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Abstract 
The initiation of adaptive immune responses requires the interactions of T cells 
with antigen presenting cells (APC) in the context of an immunological synapse 
(lS). Naïve T cell responses are dependent on the engagement of CD28 and 
CTLA-4 by CD86 and CD80, respectively amplifying and dampening the antigen 
specific signal. CD80 and CD86 cosignaling molecules display three major 
domains: a membrane distal IgV-like domain, a membrane proximal IgC-like 
domain and an intracellular domain. Crystallographic data has shown that only the 
IgV domain of CD80 and CD86 physically interacts with CTLA-4. However, 
extensive mutational analyses have also implicated the IgC domain in receptor 
binding and in the overall function of these molecules. The role of CD80 and 
CD86 within the IS and their exact molecular structure remains to be elucidated. 
The work presented in this thesis employs wild type, mutant, deleted and chimeric 
forms of CD80 and CD86 to characterize the role of their domains in molecular 
structure, receptor binding and overall cosignaling function in an antigen specific 
cellular interaction system. CD80 and CD86 are shown to be associated to the 
APC cytoskeleton. A highly conserved K4 motif within CD86 is shown to be a 
cytoskeletal association motif. Moreover, CD86 is shown to physically interact 
with ERM proteins. Only cytoskeleton-linked CD86 localizes at the IS and induce 
IL-2 production. CD80 and CD86 molecular organization is clearly established 
using cytometry-based fluorescence resonance energy transfer (FCET) and 
biochemical approaches. CD80 exists as a mixed monomeric and dimeric 
population and CD86 as a monomer in live cells. The crucial role of CD80 and 
CD86 IgC domain in multimerization is revealed. Importantly, the molecular 
structure of these molecules correlates with their binding properties and 
cosignaling function. A functional picture of CD80 and CD86 domains emerges 
where the IgV is responsible for receptor binding, the Ige domain impacts 
dimerization, and the intracellular domain functionally links these proteins to the 
cytoskeleton. The findings presented in this thesis certainly contribute to the 
general understanding of cosignaling protein interactions and functions and may 
facilitate the design of structure-based immunotherapeutics. 
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Résumé 
L'initiation d'une réponse immunitaire adaptatrice requière l'interaction d'un 
lymphocyte T et d'une cellule présentatrice d'antigène (CPA) dans le contexte de 
la synapse immunologique (SI). L'interaction entre CD28 et CTLA-4 exprimées 
par les lymphocytes T avec CD86 et CD80 présentes à la surface des CP A, 
amplifie ou inhibe le signal antigène spécifique et est absolument nécessaire. Les 
molécules de co-stimulation CD80 et CD86 comportent trois principaux 
domaines, soit un domaine IgV, un domaine IgC et un domaine intracellulaire. 
Des études cristallographiques ont démontré que seul le domaine IgV lie CTLA-4. 
Cependant, de nombreuses études ont aussi souligné l'importance du domaine IgC 
dans la fonction co-stimulatrice de ces molécules. Le rôle de CD80 et CD86 au 
sein de la SI et leur structure moléculaire doivent être établis. Le travail présenté 
dans cette thèse utilise des molécules sauvages, mutées, tronquées et chimériques 
de CD80 et CD86 afin d'étudier le rôle de leurs domaines dans la configuration 
moléculaire, l'interaction de ces molécules avec leurs récepteurs et leur fonction 
co-stimulatrice. Nous avons démontré que CD80 et CD86 sont liés au 
cytosquelette des CP A. Une séquence conservée dans tous les domaines 
intracellulaires de CD86, le motif K4, est responsable de cette association. De 
plus, une interaction entre CD86 et les protéines ERM est révélée. Seules les 
molécules de CD86 associées au cytosquelette se retrouvent dans la SI et co-
stimule la sécrétion d'IL-2. Des approches biochimiques et de transfert d'énergie 
de fluorescence par cytométrie démontrent que CD80 est monomérique et 
dimérique alors que CD86 est monomérique. Nous avons établi le rôle 
déterminant du domaine IgC dans la formation de ces multimères. De plus, la 
structure moléculaire de ces molécules corrèle avec leurs propriétés d'interactions 
et leur fonction co-stimulatrice. Nous proposons un modèle détaillant le rôle 
fonctionnel de chacun des domaines de CD80 et CD86; ainsi le domaine IgV est 
responsable de la liaison de récepteurs, le domaine IgC influence l'interface 
dimérique et le domaine intracellulaire lie ces molécules au cytosquelette. Les 
conclusions de cette thèse contribuent à la compréhension globale du phénomène 
de co-stimulation et pourraient faciliter le développement d'immunothérapies. 
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Chapter 1 
Introduction 
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1.1Immuoity 
Living organisms do not live in c10sed environments and are continuously 
assaulted by a plethora of foreign material. In humans, foreign material can be 
various bacterial, fungal, protozoan, parasitic and viral pathogens and even their 
own material that can potentiany present sorne danger such as malignant cens. 
Immunity refers to the integration of an defensive measures put in place to protect 
the organism from these dangers. 
The vertebrates' immune system is made up of two subsystems, the innate and the 
adaptive immune systems. Innate immune receptors are promiscuous and mediate 
fast responses against dangers. In contrast, the adaptive immune system mediates 
highly specific responses in a slower fashion through antigen receptors. 
Distinctively, adaptive immunity is characterized by the generation of memory 
lymphocytes that can confer faster protection upon reencounter with the same 
antigen. Innate immune mechanisms provide sufficient time to the host to 
mobilize the more slowly developing mechanisms of adaptive immunity. Both 
immune systems dialogue and their interaction is essential to mount efficient 
immune responses for organism protection. 
Organism protection is offered through the intricate actions of immune cens and 
lymphoid organs that make up the immune system. Lymphoid organs can be 
divided into two categories: the primary and the secondary lymphoid organs. The 
bone marrow and the thymus are the primary lymphoid organs and it is where 
lymphocytes are generated. Secondary lymphoid organs are the sites where 
immune responses occur; they are specialized to trap antigen and are also 
important in lymphocyte maintenance. Lymph nodes, the spleen and mucosal 
associated lymphoid tissues (MALT) are aH secondary lymphoid organs. 
Immune cens constantly patrol the organism from blood to tissues and from 
lymph to blood. Immune cens are either of myeloid or lymphoid origin. The 
myeloid lineage is composed of granulocytes, macrophages, dendritic cens and 
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mast cells. The lymphoid lineage consists of T and B lymphocytes as well as 
natural killer cells. Although B and T lymphocytes originate in the bone marrow, 
only B lymphocytes mature there while T lymphocyte precursors migrate to and 
mature in the thymus. 
1.1.1 Evolution of the immune system 
Immunity is believed to have evolved from generalized to highly specific 
reactions (1). 500 million years ago, a transposition event involving a 
recombination activating gene (RAG)-bearing element is believed to have given 
rise to the rearranging antigen binding receptors only present in jawed vertebrates 
(1). This transposition event conveyed a significant selective advantage since the 
greater the amount of genetic variation, the more adaptable the host will be. This 
transposition event is considered the defining point in the emergence of adaptive 
immunity (2, 3). The most recent ancestor of the rearranging antigen binding 
receptors would have been an immunoglobulin superfamily (IgSF) member. It 
could have either pre-existed or given rise to an immunoglobulin V -region type of 
innate immune cell surface receptor as suggested by studies of the shark new 
antigen receptor (NAR) (4, 5). Innate immunity is generally considered to be the 
more phylogenetically ancient and do es not share the specificity and memory 
aspects of adaptive immune responses. However, recent advances suggest that 
jawless vertebrates, protochordates and invertebrates can probably mount RAG-
independent immune responses (6) and sorne evidence for memory in 
invertebrates has also been presented (7). 
1.1.2 Innate immunity 
The innate immune system encompasses a collection of rapid defenses that do not 
depend on specific antigenic recognition. The simplest form of protection consists 
of mechanical barriers such as the skin epithelium or mucosal surfaces that 
prevent entry of most pathogens. The low surface pH of the epithelium prevents 
pathogen entry by inhibiting bacterial growth and also produces peptides, such as 
defensins, that have antimicrobial and immunoregulatory properties. Genomic 
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evidence has shown the possible existence of many yet uncharacterized 
antimicrobial peptides underlying their important contribution to innate immunity 
(8). The mucous secreted by gastrointestinal, respiratory and urogenital tract 
membranes traps invaders and represent another protective barrier. Moreover, the 
human body presents a normal microbial fIora that competes with pathogenic 
microorganisms for nutrients. Another level of protection brought about by the 
innate immune system is the complement system. Activation of the complement 
cascade by one of three distinct pathways leads to protective mechanisms such as 
microbial opsonization, phagocyte recruitment and microbiallysis (9). 
The cellular elements that compose the innate immune system are the eosinophils, 
that mainly respond to parasitic infections, the basophils and mast cells that 
contribute to hypersensitivity reactions through the release of granules, and the 
phagocytic cell types (monocytes, macrophages, neutrophils, dendritic cells) that 
kill engulfed material. Natural killer cells (NK cells) are also important in innate 
immunity through their cytocidal activity against infected and malignant cells that 
present deregulated major histocompatibility complex c1ass 1 (MHC c1ass 1) 
molecules at their surface. 
Through the use of germline-encoded receptors that are not clonally distributed 
(10), the innate immune cells recognize a limited number of evolutionary 
conserved motifs in pathogens. These diverse pathogen-associated molecular 
patterns (PAMPs) are also found in nonpathogenic microorganisms and the term 
microorganism-associated molecular patterns (MAMPs) has recently been 
suggested (11). P AMPs, such as lipopolysaccharides (LPS), mannans, teichoic 
acids, denatured DNA, and bacterial DNA, can be categorized into lipid, protein, 
or nuc1eic acids (10, Il). These PAMPs are recognized by pathogen-recognition 
receptors (PRR) (10). 
Toll-like receptors (TLR) are a particularly important group of the PRR. Ten TLR 
have been identified in humans (10, 11). TLR are type 1 membrane proteins with 
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an extracellular domain presenting a structure called the leucine-rich repeat that is 
involved in ligand recognition. Intracellularly, most TLR contain a TIR 
(Toll/interleukin-IR) domain that interacts with the adaptor protein MyD88 
(myeloid differentiation factor88) that couples with the serine/threonine IRAK 
(IL-I receptor-associated kinases) leading to signal transduction. Each TLR 
activates similar signaling pathways, but sorne TLR trigger their specific 
pathways depending on which cytoplasmic adaptors they associate with. 
Regardless of the specific pathway induced, most TLR signaIs leads to the 
activation of a master switch in inflammation induction: transcription factor 
nuc1ear factor-kB (NF-kB) (12). NF-kB induction will trigger the release of pro-
inflammatory cytokines inc1uding IL-6, IL-I2 and TNF-a (11), antimicrobial 
peptide secretion and direct pathogen killing. The secreted pro-inflammatory 
cytokines will activate surrounding cells to produce chemokines or adhesion 
molecules helping in the recruitment of inflammatory cells into the infection sites. 
1.1.3 Adaptive immunity 
Unlike innate immunity that makes use of a fixed repertoire of inherited receptors, 
the potency of adaptive immunity resides in its capacity to generate billions of 
different antigen receptors from multiple gene segments assembled by somatic 
recombination to create unique antigen receptors capable of recognizing virtually 
any antigen. T and B lymphocytes are the cellular elements of the adaptive 
immune system. The generation of the T cell antigen receptor (TeR) and the B 
cell antigen receptor (BeR) is a complex process that creates an impressive 
repertoire through combinatorial joining. RAG enzymes initiate gene 
rearrangement. TeR are somatically rearranged from variable, diversity and 
joining gene segments to generate Vala and VpDplp chains. A similar process 
than that used for the TCR brings about the BCR variability. Following 
rearrangement and selection, T and B cells leave the thymus and bone marrow 
and circulate within the body. Prior to antigen encounter, lymphocyte homeostasis 
involves short-lived seriaI contacts of low signal intensity with dendritic cells in 
the lymph node providing sub-threshold survival signaIs (13). Following antigen 
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exposure and response, sorne T and B cells will persist within the organism to 
provide rapid and specifie responses upon antigen reencounter, a hallmark of 
adaptive immunity known as immunological memory. 
1.1.3.1 T cell memory 
Distinctively, adaptive immunity is characterized by its capacity to generate 
memory lymphocytes that have been c10nally expanded following antigen 
encounter and that persist within an organism to provide rapid and specifie 
responses to re-infection. Memory T cells can be divided into non-polarized or 
polarized phenotype, namely central memory and effector memory cells (14). 
Central memory T cens are non-polarized cells that express lymph no de homing 
receptors such as CCR 7 and that primarily migrate between blood and lymph 
nodes in a pattern similar to that of naïve T cells. Central memory T cells serve 
primarily as long-lived reservoirs of immunological memory. When stimulated 
with antigen, these cens give rise to additional central memory cens as well as 
effector memory T cells. Effector memory T cells are polarized, terminany 
differentiated T cens that are shorter lived and provide immediate protection to 
pathogens in peripheral tissues (14). 
1.1.4 Dendritic cells: linking innate and adaptive immunity 
Effective immune responses involve the concerted action of the innate and 
adaptive immune systems through the sentinel function of dendritic cells (DC). 
DC develop in the bone marrow and migrate in an immature form to the 
peripheral tissues where they will take up antigens from the environment. These 
cens express high levels of most TLR and dangers such as exposure to P AMPs 
and inflammatory mediators (15) will induce their migration to lymphoid organs 
via the blood or the lymph, a property which has not been described for other 
APc. Danger detection by DC will also lead to their maturation. DC maturation 
involves antigen processing and presentation in the context of major 
histocompatibility complex c1ass II (MHC c1ass II) molecules. DC have the 
capacity to present antigens encountered in peripheral tissues due to the dramatic 
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shift in MHC class II half-life that allows accumulation and persistence (over 100 
h) of the peptide:MHC complexes formed (16, 17). Maturation also induces 
upregulation of costimulatory molecules expression and only costimulation-suited 
mature DC (mDC) can activate the two cellular elements (T cells and B cells) of 
the adaptive immune system (18). In secondary lymphoid organs, antigen-loaded 
DC will encounter antigen-specific T cells and initiate adaptive immune 
responses. DC are therefore crucial in linking innate to adaptive immunity (18) 
and this linkage allows proper protection of the organism. 
1.2 The major histocompatibility complex 
The MHC is the most important genetic region in the human genome with respect 
to both innate and adaptive immunity. Roughly, a third of the expressed 
transcripts identifiable within the MHC fall into the following immune functions: 
antigen processmg, antigen presentation, immunoglobulin superfamily, 
inflammation, leukocyte maturation, complement cascade, non-classical MHC 
class 1 receptor family, immune regulation and stress response (19). The variety of 
immune functions encoded at that region might explain its association with 
hundreds of immune related diseases (20). The MHC region is located on the 
short arm of the human chromosome 6 (6p21.3). The first gene map of human 
MHC (classical MHC map) was published in 1999 and was shown to coyer 
approximately 4 Mbp of DNA within the human genome (21). The presence of 
MHC relevant genes beyond the set MHC boundaries led to the idea of an 
extended MHC. The MHC locus as now been extended (xMHC) and spans 7,6 
Mbp (19, 22, 23). The main gene clusters associated with the MHC are tRNAs 
(157 genes), histones (66 genes), zinc fingers (36 genes), olfactory receptors (33 
genes), class 1 genes (26 genes) and class II genes (24 genes) (19). The fact that 
tRNAs and histones are the two largest c1usters in the MHC indicates that this 
genome region is an expression hotspot. Because class 1 and c1ass II molecules 
were first identified on the surface of human leukocytes, they are also referred to 
as human leukocyte antigen (HLA). HLA class 1 and HLA class II regions encode 
for cell surface g1ycoproteins responsible for antigen processing and presentation. 
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1.2.1 HLA class 1 gene cluster 
The HLA class 1 c1uster comprises the highly polymorphic c1assical c1ass 1 genes 
(HLA-A, -R and -C), the less polymorphic non-c1assical c1ass 1 genes (HLA-E, -F, 
-G and 12 pseudogenes) and the c1ass I-like genes (MICA, MICR, and 5 
pseudogenes) (19). MHC c1ass 1 a chain alleles are co-dominantly expressed; 
individuals homozygous for all three c1ass 1 loci (HLA-A, Band C) express three 
different MHC c1ass 1 while heterozygous individuals can express six. 
1.2.1.1 MHC class 1 molecule 
The c1assical MHC c1ass 1 molecules are expressed at the surface of all nuc1eated 
cells. The main function ofMHC class 1 molecules is to present cytosolic antigens 
to CDS T cells. MHC c1ass 1 proteins are heterodimeric in structure. They consist 
of the non-covalent association between a polymorphic a chain and a small 
monomorphic soluble protein called p2-microglobulin (p2m). The a chain is 
composed of three extracellular domains, al, a2 and a3. It is the fold between 
the al and a2 domains that creates a c1eft in which the antigenic peptide lies. 
Polymorphism is mainly concentrated in the peptide-binding c1eft thereby 
affecting the array of peptides that can be presented to T cells. The MHC c1ass 1 
c1eft can accommodate peptides of S to 10 residues although nonamers have been 
shown to be favored (24, 25). Peptides binding to a specific c1ass 1 allele show 
sorne conserved anchor residues. 
1.2.1.2 Peptide processing and loading of MHC class 1 
molecules 
MHC c1ass 1 molecules usually display self-peptides derived from self-proteins 
that were targeted to proteasome-mediated degradation. The 26S proteosomal 
complex is composed of a 20S catalytic subunit and fifteen regulatory subunits 
known as the 19S regulatory complex (26). In the presence of inflammatory 
cytokines such as TNFa and IFNy, three proteolytic subunits are replaced to form 
the immunoproteasome (27). The formation of such a complex enhances antigen 
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processing efficiency (27). The peptides generated in the cytoplasm from the 
proteasome are picked up from an ER (endoplasmic reticulum) resident 
transmembrane heterodimeric complex called T AP (!ransporters associated with 
~tigen grocessing) complex. This complex drives peptide translocation from the 
cytosol to the ER lumen where newly synthesized MHC c1ass 1 molecules await 
loading. Within the ER lumen, MHC c1ass 1 complexes are bound to a chaperone 
named calnexin. Once the a chain binds to p2m, two other chaperones called 
calreticulin and tapasin bind to the newly formed heterodimeric complex. Tapasin 
links the TAP transporter to the MHC c1ass 1 complex, catalyzing peptide loading 
in the MHC peptide binding groove (28, 29). The peptide loaded MHC c1ass 1 
molecules can then exit the ER through the Golgi to the plasma membrane 
following the default secretory pathway. The MHC c1ass 1: peptide complexes are 
now ready to interact with CD8 T lymphocytes. 
1.2.1.3 Non-classical MHC class 1 molecules 
The non-c1assical MHC c1ass 1 molecules have variable function, expression and 
distribution. HLA-E and HLA-G bind to NK specifie receptors. This MHC c1ass 1 
innate immunity linkage is also shown by molecules such as MICA and MICB, 
which are upregulated by stress signaIs and that activate cells through the NKG2D 
receptor (30). 
1.2.1.4 CD1 molecules 
CD1 molecules are MHC-like molecules that bind p2m. In contrast to MHC c1ass 
1 molecules CD1 molecules (CD1 a to e) bind to lipid-based molecules thereby 
diversifying immune recognition. 
1.2.2 Antigen presenting ceUs 
APC are cells that collect and c1eave antigens to present them in the context of 
MHC c1ass II and that constitutively or inducibly express cosignaling molecules. 
The three types of APC, dendritic cells, B cells, and macrophages, differ in many 
aspects such as their morphology, their actin cytoskeleton structure and their cell 
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surface molecules expreSSIOn. APC also produce different amounts of pro-
migratory chemokines and although expression-profiling studies do not allow 
direct comparison of chemokine production by different types of APC, it is clear 
that activated DC and macrophages, but not B cells, can generate a pro-migratory 
environment that attracts passing leukocytes (31). 
1.2.2.1 Dendritic ceUs 
DC have diverse shapes with long actin-rich dendrites. Immature DC (iDC) 
engulf pathogens and deliver them to the nearest lymph no de for T cell 
presentation. iDC express intermediate levels of MHC class II molecules and 
cosignaling molecules and upon maturation, upregulate the cell surface expression 
of both types of molecules by three to tenfold (17). As shown by inhibition 
studies, actin dynamics in DC, but not in other APC, are essential for immune 
response initiation (32-35). 
1.2.2.2 Macrophages 
Macrophages are round, phagocytic cells that rearrange their actin cytoskeleton 
upon the crosslink of their innate receptors initiating signaling that leads to 
pathogen engulfinent. The ingestion of pathogens also activates antimicrobial 
killing mechanisms and stimulates the production of inflammatory mediators. 
Macrophages express low levels of MHC class II and cosignaling molecules prior 
to activation, an expression that is strongly upregulated after maturation in the 
presence oflFNy and GM-CSF (36, 37). 
1.2.2.3 B ceUs 
Naïve B cells are round cells with a simple cortical actin cytoskeleton but 
activation leads to a more complex cytoskeleton (38). B cells principally function 
as APC in secondary lymphoid organs where class II restricted antigen 
presentation enables the cognate B:T cell interactions required to elicit T cell 
dependent humoral immunity (39). Naïve B cells express low levels of MHC and 
cosignaling mole cules at the surface, but this expression is strongly upregulated 
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after maturation. Contrary to the two other APC types, B cells are not actively 
phagocytic. Rather, they use their BCR for antigen recognition and engulfment. 
The BCR is a membrane bound immunoglobulin (lg) coupled to a non covalent 
19a and Ig/3 heterodimer. 19a and Ig/3 signaling leads to B cell activation and 
triggers antigen intemalization via clathrin coated pits (40). 
1.2.3 The HLA class II gene cluster 
The HLA class II cluster comprises the highly polymorphic, classical class II 
genes (HLA-DP, -DQ, -DR and pseudogenes) and the less polymorphic non-
classical class II genes (HLA-DM and -DO). 
1.2.3.1 MHC class II molecules 
Unlike MHC class l, which is present on all nucleated cells, MHC class II 
molecules are mainly found on APc. They can also be found constitutively on 
other cell types such as the thymic medulla or cortical epithelial cells, following 
IFNy induction on fibroblasts, mast cells, and endothelial cells or following 
activation on T cells (41). The main function of MHC class II molecules is to 
present exogenous antigens to CD4 T cells. MHC class II proteins are 
heterodimeric in structure. They consist of the non-covalent association between 
an a chain and a /3 chain. In contrast to the monomorphic a chain, /3 chain alleles 
of each locus (HLA-DR, DP, DQ) are polymorphic and co-dominantly expressed. 
Both the a and /3 chains are composed of two extracellular domains, 
transmembrane domains and short cytoplasmic tails. It is the membrane distal 
domains of both chains (a 1 and /31) that form the peptide-binding groove. In 
contrast to MHC class 1 binding cleft, the peptide binding groove ofMHC class II 
is open at both end and can accommodate peptides of 12 to 30 amino acids, often 
encompassing a core sequence (24), with a preferred size of 15 amino acids (24, 
25,42). 
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1.2.3.2 Non-classical MHC class II molecules 
The less polymorphic non-c1assical c1ass II genes are not expressed on the cell 
surface but are involved in peptide ex change and loading on c1ass II molecules 
(43). HLA-DM is expressed by the same cell types as the c1assical MHC II 
molecules while the expression of HLA-DO appears to be restricted to B 
lymphocytes, subsets of DC, and cortical and medullary epithelial cells of the 
thymus (44). 
1.2.3.3 Peptide processing and loading of MHC class II 
molecules 
MHC c1ass II molecules present extracellular antigens degraded through the 
endocytic route. Access to the endocytic route can occur in multiple ways 
depending on which APC engulfed antigen (39). The endocytic route can be 
divided in three main compartments: early endosomes, late endosomes and 
lysosomes. Reduction and c1eavage of antigen in early and late endosomes 
involves enzymes such as gamma-interferon lysosomal thiol reductase (GILT), 
endopeptidases and exopeptidases (41). In lysosomes, antigen processing occurs 
through cysteine proteases called cathepsins. MHC c1ass II transactivator 
molecule (CIlTA) regulates the expression of MHC c1ass II molecules. The a and 
P chains are co-translationally inserted into the membrane of the ER where they 
will form heterodimers. These heterodimers will interact with the nonpolymorphic 
invariant chain (Ii) predominantly through its CLIP (c1ass II associated invariant 
chain geptide) domain (45) that binds to MHC c1ass II molecules in a similar 
manner than antigenic peptides (46). This binding favors proper folding of c1ass II 
molecules and prevents the binding of endogenous peptides to c1ass II molecules. 
Properly folded nonameric complexes composed of three heterodimers bound to 
an Ii trimer will be exported from the ER to the Golgi. Golgi resident nonameric 
complexes will then be targeted to endosomal organelles due to sorting signaIs 
present in the cytoplasmic domain of Ii (47). These endosomal organelles are 
referred to MHC c1ass II compartments (MIlC). In MIlC, Ii will be c1eaved 
resulting in the release of MHC c1ass II heterodimers bound to CLIP. The MHC 
c1ass IVCLIP complexes will then be transported to other organelles where HLA-
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DM is present. HLA-DM catalyzes the dissociation of CLIP, stabilizes the now 
empty MHC class II and assist in peptide selection favoring peptides with high 
affinity (48). HLA-DO can assist the peptide editing function of HLA-DM in B 
cells, although its exact role is still debate matter (44). Finally, peptide loaded 
MHC Class II molecules exit and are transported to the cell surface where they 
can fulfill their function of presenting antigen to CD4+ T cells. 
1.2.3.4 MHC class II signaling 
Apart from their main antigen presentation function, growmg evidence 
demonstrate a signaling role for MHC class II proteins. Indeed, upon MHC class 
II ligation, intracellular signaling pathways impacting cellular adhesion (49), 
cytokine gene expression (50, 51), and proliferation, maturation and apoptosis of 
APC are induced (52). MHC class II localization in specific plasma membrane 
compartments and its interaction with given receptor-associated molecules are key 
in this signal transduction function (53). Although no known signaling motifs 
have been found in the short cytoplasmic tail of MHC II molecules, the 
transmembrane and cytoplasmic regions of these proteins have been shown to 
signal by coupling to other receptor-associated effector molecules for signal 
transduction (54). Moreover, the intracellular domains ofHLA-DR molecules are 
important for cytoskeletal association following oligomerization (55). In B cells, 
MHC class II molecules associate with CD79a/CD79b, CD20, and CDI9, and in 
monocytes, a CD18IMHC class II complex has been identified (54, 56, 57). 
Recently MHC class II associations with other cell receptors were reported in DC 
(53). Moreover, several studies have shown the importance of lipid rafts in 
regulating MHC class II signaling and APC activity and raft-associated MHC 
class II molecules were shown to accumulate at the IS and facilitate T cell 
activation (58-60). Disruption of lipid rafts impairs MHC II peptide presentation. 
The proportion of MHC II molecules constitutively localized to lipid rafts appears 
to vary depending on the APC type and its activation status (53). The 
translocation of MHC II molecules into lipid rafts occurs independently of their 
intracytoplasmic domains (60). MHC class II triggering activates intracellular 
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tyrosine phosphorylation through Src family tyrosine kinases. In addition, MHC 
class II signaling regulates the activity of the MAP (mitogen .ê,ctivated 12rotein) 
kinases, such as Erk (~xtracellular signal-related kinase) in human monocytic and 
B celllines (56,60) and p38 in monocytes (61). PKC (protein kinase C) mediated 
signaling is also important for MHC c1ass II mediated actin polymerization and 
cytoskeletal organization (53, 62). MHC class Il signaling causes actin 
reorganization in mature DC (63), contributing to the formation of the 
immunological synapse (lS) during DC:T cell interactions. Finally, MHC class II 
signaIs appears to maximize the delivery of MHC c1ass II: peptide complexes to 
the surface during the DC:T cell interaction (32). 
1.2.3.5 al3 T cells recognize MHC:peptide complexes 
Two populations of T ceUs distinguished on the basis of TCR expression exist. yD 
T ceUs represent about 5% of aU circulating T ceUs and are particularly enriched 
in epithelial-rich tissues such as the skin, intestine and reproductive tract (64). 
These cells can undergo gene rearrangement in the thymus but most of them do so 
in an extrathymic compartment (64). In contrast to the other type of T cells, yD T 
cells are not MHC restricted and recognize soluble proteins and non-protein 
antigens of endogenous origin. The major c1ass of T cells recognizing peptide 
antigens in complex with c1ass 1 or c1ass II MHC proteins are T cells expressing 
an al3 TCR. These cells can be further divided into two main classes, i.e. CD4 
expressing T ceUs that regulate the cellular and humoral immune responses and 
cytotoxic CD8 T cells that are responsible for killing of cells infected 
intracellularly and that present peptide:MHC class 1 complexes at the ceU surface 
(65). CD4 T lymphocytes and CD8 T lymphocytes have different but 
complementary functions during immune responses. CD4 constitute roughly 60% 
of T ceUs present in the blood and secondary lymphoid organs while CD8 
represent around 40%. The work presented in this thesis is concentrated on al3 T 
cells of the CD4 lineage. 
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1.3 Naïve T cell activation 
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Figure 1 The Two Signal Model (from (1» TCR Interaction with peptide-MHC 
class II presented by dendritic cells acts as signal 1 for T cell activation. Signal 
two consists of co-receptor and co-ligand interactions and can be either positive, 
leading to cell activation, or negative, leading to co-inhibition. 
1.3.1 Two signal theory of T cell activation 
The 'two signal' concept of lymphocyte activation was first proposed by 
Bretscher and Cohn and refined by many scientists (reviewed in (66)) trying to 
explain discrimination of self from nonself (67, 68). When the theory was first 
proposed, neither the TCR nor any cosignaling receptor-ligand interaction had 
been identified. As depicted in figure 1, the two signal theory postulates that two 
signaIs are required for activation of naïve T cells. Because T cell activation by 
costimulation is more complex than originally envisioned, the two signal model 
somewhat oversimplifies the contribution of each signal; however the essence of 
this model remains suited for the understanding of T cell activation. 
1.3.1.1 Signal 1 : the antigen specifie signal 
Signal 1 is an antigen specific signal that occurs when the TeR binds to antigenic 
peptides presented by MHC molecules. A single TCR can recognize structurally 
distinct MHC peptide complexes (69). The overall structure of the aJ3 TCR is 
composed oftwo chains, the a and J3 chains, that exhibit an IgV-like and IgC-like 
domain architecture reminiscent of the IgSF and are linked by a disulfide bond in 
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the hinge reglOn, close to the membrane. Upon binding to a peptide/MHC, 
conformational changes are induced in the hypervariable loops (CDR loops) of 
the TCR (70). CD4 and CD8 co-receptors also bind to MHC/peptide along with 
the TCR and affect the qualitative nature of the binding (70). Differences in 
binding affinity, kinetics, or surface density, can lead to very different T cell 
responses. T cells have the capacity to detect as few as 10 specific peptide-MHC 
ligands on cells (71, 72) and even when presented with very low levels of 
peptide-MHC, a substantial proportion of TCR are ligated in the process of T cell 
activation (73). Delivered alone, signal one does not results in T cell activation; 
rather it leads to astate ofunresponsiveness called anergy (74). 
1.3.1.2 Signal 2: cosignaling 
Signal 2 involves the interaction of a cosignaling receptor at the T cell surface 
with its counter receptor at the APC surface. Cosignaling molecules are cell 
surface molecules that cannot functionally activate T cells on their own, but rather 
amplify or counteract signaIs provided by signal 1 (75, 76). While prolonged TCR 
signaling is necessary for T cell activation, a recent report has shown that 
persistent cosignaling is also required to allow naïve T cells activation (77). 
Cosignaling molecules either belong to the IgSF (including the CD28, the B7 and 
the SLAMISAP sub-families) or the TNF superfamily. Numerous receptor-ligand 
pairs in each of these two families can play a co-activating or co-inhibiting role at 
various T cell activation stages (78). The balance between negative signaIs from 
co-inhibitory receptors and positive signaIs from co-stimulatory receptors 
therefore dictates the ensuing response. Two interacting pairs are key in naïve T 
cell responses: the co-activating pair CD28:CD86 and the key co-inhibiting pair 
CTLA-4:CD80. 
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1.3.2 Primed T cells activation 
In contrast to naïve T cells, primed T cells have a low activation threshold (79). A 
short TCR stimulation equivalent to about 30 minutes of receptor occupancy in 
the absence of CD28 engagement is sufficient to trigger proliferation and cytokine 
production; an even shorter stimulation triggers cytotoxic CD8 T cell responses 
(79,80). 
1.3.3 Positive and negative selection 
During the recombination process that generates the antigen receptors, many unfit 
TCR and BCR are generated. During T cell development in the thymus, 
thymocytes move across antigen-presenting thymie epithelial cells in the cortical 
epithelium of the thymus where they are tested for their affinity for self-MHC 
molecules; this process is known as positive selection (81). During positive 
selection, CD4/CD8 lineage choice is determined by the duration of TCR 
engagement (82, 83). Cosignaling via CD80 and CD86 molecules expressed on 
thymal dendritic and medullary epithelial cells was also suggested to regulate 
CD4 and CD8 T cell differentiation since CD80/CD86 deficient animaIs showed 
CD4 skewing while CD80 or CD86 transgenic animaIs showed CD8 T cell 
skewing (84). Positively selected cells then go through a negative selection round 
by DC residing in the thymie medulla which rem oves self-specifie T cells (85). B 
cells differentiation takes place in the bone marrow where somatic recombination 
occurs. This process takes place in the absence of antigen; it is only in peripheral 
tissues that B cells can further mature under the influence of T cell help and 
antigen where they can isotype switch and affinity mature by acquiring somatic 
hypermutations (86). 
1.3.4 Central and peripheral tolerance 
The elimination of autoreactive B and T cells in the thymus and bone marrow 
through negative selection is called central tolerance. Sorne self reactive cells can 
escape this negative selection if their MHC:self-peptide recognition is not of high 
enough affinity and also because not all self-antigens are presented in the thymus 
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or bone marrow. Tolerance in the periphery complements central tolerance and 
helps in autoimmunity prevention. Peripheral tolerance can occur due to the lack 
of costimulatory signaling that leads to deletion or anergy of the responding T cell 
(87) or through additional subsets of cells inc1uding DC and regulatory T cells 
(Tregs) (88). Two main categories of CD4+ Tregs exist (89). The first type is the 
naturally occurring Foxp3-dependent CD4+ CD25+ that are produced in the 
thymus and expresses high levels of CTLA-4 (89). CD281B7 interactions are of 
crucial importance in the control of CD4+ CD25+ Tregs homeostasis (90). 
Studies have also indicated that CTLA-4 has a crucial role in regulating peripheral 
tolerance as a consequence of CTLA-4-CD80/CD86 interactions (91, 92). The 
second type of Tregs are the inducible Tregs and are Foxp3-independent, secrete 
IL-IO and occur following tolerogenic encounters in the periphery (89). Such 
tolerogenic encounters might involve bi-directional CD80/CD86:CTLA-4 
signaling (from DC: Treg interactions), inducing tolerogenic tryptophan 
catabolism (93, 94). 
1.3.5 The immunological synapse 
Cellular interactions between migrating T cells and mDC in lymphoid organs 
leads to the onset of morphological changes, cell surface receptors recruitment at 
the interaction interface, remodeling of the cytoskeleton and signaling, ultimately 
leading to the transcription of specific genes. During the interaction, receptors at 
the interacting APC surface also become engaged and transmit signaIs that lead to 
APC maturation or death. The term immunological synapse (IS) refers to the 
contact site between an interacting T cell and an APC since signal exchange 
between the two immune cells is reminiscent of neuronal synapses (95). In 
original descriptions (96, 97) only contact interfaces exhibiting specific 
rearrangement patterns were termed IS. Nowadays, molecular segregation within 
a contact interface is not a prerequisite for it to be referred to as IS and several 
unsegregated IS have been shown to transmit a full range of signaIs such as the 
non-specific IS, the early IS and the IS formed between naïve T cells and DC 
(98). 
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The interaction mode is determined, in part, by the type and activation state of the 
APC and where the IS is formed. The type and duration of the cellular interaction 
seems to be inversely correlated with the APC activation potency and cytoskeletal 
activity. As previously stated, the most recognized form of synapse consists of 
receptor enrichment at the contact site. This pattern represents the mature stage of 
an IS. In a mature synapse, a central structure called the central supramolecular 
activation c1uster (cSMAC) is enriched with TCR and CD28 and other signaling 
receptors (99). Surrounding the cSMAC is the peripheral SMAC (PSMAC), 
mainly enriched with adhesion molecules (99). Recent reports have characterized 
other markers for the pSMACs such as VLA4 (100), ADAP (101) and the 
transferrin receptor (102). The distal zone of the synapse where no cellular 
interface is formed is referred to as the distal SMAC (dSMAC) and is known to 
be enriched in CD45 (103). 
In original descriptions, the main function of the IS was believed to be signaling 
initiation. It now appears c1ear that signaling is actually initiated prior to IS 
formation (104) and the cSMAC main function is to favor a cosignaling 
environment. The synapse generates a microenvironment favoring secondary 
events such as costimulatory and cytokine signaling and plays a central role in the 
delivery of full effector function via directed secretion (105, 106). However, sorne 
reports indicate that the cSMAC may enhance TCR signaling induced by low 
affinity agonists (107). Clearly, the role of the synapse might differ depending on 
what type of antigen is being presented. The IS is dynamic in nature as shown by 
studies demonstrating that a T cell will detach from an APC when presented with 
an alternative APC presenting higher antigen amounts (108). 
Although the IS has mainly been studied between APC and CD4 T cells, synapse 
structures have also been described for CD8 T cells (109-111) and for natural 
killer cells, and in sorne cases in the absence of antigen (98). During cytolytic 
synapses, the narrow c1eft formed between the membranes of interacting cells, 
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allows for the directional secretion of granules containing granzymes, perforin, 
and lysosomal proteins. 
1.3.5.1 The cytoskeleton and the IS 
As in neuronal synapses, the cytoskeleton plays a crucial role in cellular 
communication (95). At the IS, the cytoskeleton plays two main function. It first 
helps in its formation by regulating movement of molecules and membrane 
domains and secondly, it serves as a scaffold for signaling platforms to huild on 
(103, 112). The contact between T cells and APC leads to actin and microtubule 
cytoskeleton polarization and transport of intracellular vesicles, cell surface 
receptors and signaling molecules to the contact site (113, 114). The portion of the 
actin cytoskeleton and its associated proteins that lies just beneath the plasma 
membrane is referred to as the cortical cytoskeleton and is important in IS 
formation and maintenance. 
1.3.5.1.1 ERM proteins 
ERM (~zrin, radixin, moesin) pro teins are a major component of the cortical 
cytoskeleton and are involved in membrane-cytoskeletal associations (figure 2) 
(115). These proteins are particularly important in IS formation and maintenance 
(116-120). Following antigen recognition, ERM proteins have been shown to he 
rapidly and transiently dephosphorylated in T cells disconnecting the cortical 
actin cytoskeleton from the plasma membrane. Such dephosphorylation favors T 
cell and APC conjugation due to the decreased rigidity of the interacting T cell. 
This dephosphorylation was observed maximally within the first minute of TCR 
engagement followed by rephosphorylation of ERM proteins within 3 minutes 
(121). ERM proteins have been shown to be clustered at the IS in their active 
serine/threonine phosphorylated form and to localize in lipid rafts following TCR 
and/or CD28 triggering (117). ERM proteins have been suggested to form an 
anchor for lipid raft associated signalosomes (117). 
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Two confonnational states have been described for ERM proteins and are shown 
in figure 2: a folded donnant fonn, soluble in the cytoplasm, and an unfolded 
active state that link transmembrane receptors to the cortical actin cytoskeleton. 
These confonnation changes are regulated by phosphorylation of a conserved 
threonine residue in the C-tenninal domain of the proteins. This phosphorylation 
disrupts the intramolecular association between the N- and the C-tenninal 
domains leading to unfolding of the proteins. The C-tenninal domain contains an 
actin-binding site, whereas the N-tenninal domain interacts with the cytoplasmic 
domains of different molecules, including CD44, CD43, ICAM-1, ICAM-2, 
ICAM-3, and VCAM-1 (115). Most of the ERM interacting proteins contain a 
positively charged amino acid cluster at a juxtamembrane position that detennines 
their association with ERM proteins. ERM molecules have also been implicated 
in cell signaling upon tyrosine phosphorylation of their intracellular domain (117, 
122-126). 
1-
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Figure 2 ERM Proteins Link Transmembrane Receptors to the Cytoskeleton 
(adapted from (127) ERM proteins exist in a donnant fonn in the cytoplasm. 
Phosphorylation of their C tenninal portions recruits ERM proteins to the plasma 
membrane. Activated ERM proteins can then associate with transmembrane 
pro teins linking them to the cortical cytoskeleton. 
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1.3.5.2 Membrane microdomains in the IS 
The plasma membrane is not a homogenous lipid bilayer and contains various 
microdomains such as lipid rafts and tetraspans that can impact immune cell 
function. Lipid rafts (also known as GEMs and DIGs) are are as of the plasma 
membrane that are rich in cholesterol, glycosphingolipids, signaling proteins and 
GPI (glycosylphosphatidylinositol)-anchored proteins. These lipid microdomains 
are thought to play an important role in the localization of signaling proteins to 
the IS. For example, the TCR, its coreceptor CD4, and the Src kinases Lck and 
Fyn are recruited to these microdomains during T cell activation (128-130). 
Cosignaling events also mediate raft aggregation to the site of the synapse (131). 
APC molecules such as MHC c1ass II and CD86 have also been shown to localize 
to rafts (132, 133). Tetraspan proteins (e.g. CD81, CD82, CD9, CD20, CD63) are 
ubiquitous membrane proteins that have the ability to interact with themselves, 
allowing them to organize a functional microdomain named the tetraspanin web 
or tetraspanin-enriched microdomain (TEM). Several proteins, inc1uding MHC 
c1ass II, CD80 and CD86 have been shown to localize in tetraspans (134-136). An 
interplay has even been shown between tetraspans and lipid rafts in APC (137). 
Tetraspans can indeed serve as links between membrane receptor complexes, lipid 
rafts and the actin cytoskeleton (138, 139) Plasma membrane 
compartmentalization certainly increases antigen presentation, signaling activity 
and binding avidity of resident proteins and impact immune cell function. 
1.3.6 Steps in immunological synapse formation 
Five main steps leading to IS formation can be distinguished (98, 140). 
Progression through all of these phases requires sustained MHC:peptide-TCR 
interaction, sustained cosignaling, sustained membrane-proximal signaling and an 
intact cytoskeleton. An overview of the IS and its key receptor interactions and 
signaling events is presented in figure 3. 
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1.3.6.1 First step: cellular scanning, contact acquisition and 
adhesive arrest 
In lymphoid organs, naïve CD4 T cells undergo a series of short-lived dynamic 
interactions with different DC, a process known as scanning (16, 87). During the 
scanning process, the cortical actin cytoskeleton of T cells is less tethered to the 
plasma membrane, allowing more efficient conjugation between the two cell 
membranes (121). When moving T cells recognize cognate peptide: MHC 
complexes, a transient arrest in migration, known as the stop signal, occurs (141) 
and leads to the arrest of adhesion-based interactions. 
1.3.6.2 Second step: TeR signaling and early IS assembly 
TCR signaling precedes IS formation (104) and TCR induced signaling leads to 
early IS assembly. The TCR is associated to the CD3 complex invariant accessory 
chain complex (CD3y, CD3ô, and CD3E and CD3ç chains) that is responsible for 
signal transduction upon binding of the MHC: peptide complex at the APC 
surface. Within the first few seconds of contact, calcium signaling is detected 
(142) and its duration and intensity is a direct function of the strength of TCR 
signaling (143). PI3K activation and signaling is also an early event of TCR 
signaling (144-146). The cytoplasmic domains of the CD3 chains contain 
immunoreceptor lyrosine-based ~ctivation (IT AM) motifs that are phosphorylated 
by Lck and Fyn leading to an activation cascade involving Zap70, LAT and 
SLP76 (104). Activation of these proteins leads to the stimulation of PLC 
(phospholipase C) and activation ofPKC and MAPK (99, 147). Activation of the 
small GTPases Ras and Rho promote actin dynamics in the contact zone (148). 
Altogether, T cell signaling will lead to the activation of genes important for 
lymphocyte proliferation and differentiation through the action of transcription 
factors NF-kB, API and NFAT. Interactions with agonist peptide: MHC 
complexes, but not antagonist or null peptide favors stable and prolonged T cell-
APC interactions (58, 147). 
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1.3.6.3 Third step: IS maturation and receptor segregation 
Upon continuous T cell:APC interaction, a mature IS forms at the cellular 
junction (99, 144) leading to the enrichment of given receptors such as the TCR, 
CD28 and cytokine receptors in the cSMAC. A pSMAC composed of adhesion 
molecules, and a more distal zone, the dSMAC, can also be observed (103). 
1.3.6.4 Fourth step: TeR internalization 
After sustained signaling, the TCR is intemalized from the cSMAC into 
cytoplasmic vesic1es, limiting its availability at the interaction interface. Along 
with co-inhibitory signaling, this results in a reduction of signaling intensity and, 
ultimately leads to the fifth phase of the IS. 
1.3.6.5 Firth step: IS dissolution 
The processes that control IS resolution and T cell detachment are unc1ear. The 
proposed mechanisms inc1ude activation-related TCR intemalization (149); 
upregulation and recruitment of coinhibitory receptors such as CTLA-4 (150, 151) 
expression of chemokines or chemokine receptors that reduce adhesiveness and 
initiate T cell motility (152) and redistribution of competing adhesion molecules, 
such as CD43 into the contact zone. During detachment, portions of the T cell 
membrane can remain attached to the APC (and vice versa), possibly causing 
focal zones of continued signaling (153). 
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cSMAC pSMAC 
Figure 3 Immunological Synapse and Signaling (adapted from (98» Following TCR 
triggering by peptide-MHC complexes, Lck relocalizes to lipid rafts and becomes 
activated. Lck activation is enhanced through co-stimulation by interactions 
between CD28 and CD86. Activated Lck engages Fyn through tyrosine 
phosphorylation, and together, Lck and Fyn phosphorylate ITAMs present in 
various molecules such as the CD3 chains and ZAP70 that will function as 
docking sites for adaptor and signaling proteins. ZAP70 phosphorylates the raft-
associated adaptor prote in LAT, which will serve as a platform for signaling 
molecules, including PLC, PI3K and SLP76. PLC.-liberates inositol-I,4,5-
tri spho sphate (lnsP3) from membrane phosphatidylinositol-4,5-bisphosphate 
(Ptdlns( 4,5)P2). DAG activates prote in PKC-which is involved in the activation 
of the downstream transcription factors NF-KB and API. In regions of more 
stringent adhesion, such as the pSMAC, talin links interactions between LF Al 
and ICAM-I to the actin cytoskeleton. As well as actin filaments, microtubules 
and the MTOC polarize towards the immunological synapse and form a scaffold 
for vesicle transport and signaling molecules. 
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1.3.7 The IS from an APC point ofview 
The organization of proteins and the cytoskeleton on the APC side of the IS is less 
well defined. However, increasing evidence show that APC play an active role in 
IS formation and maintenance (154). APC provide multiple signaIs for T cells that 
are dependent on the APC cytoskeletal activity (34, 35). Although CD28 
accumulates at the IS without any interaction, Pentcheva-Hoang et al. (155) have 
shown that its counter-receptor at the APC surface, CD86, stabilizes it at the IS. 
On the other hand, CD80 preferentially recruits and stabilizes CTLA-4 to the 
synapse. Moreover, Tseng et al. (156) showed that ligand stability on the APC 
side can also affect receptor recruitment since CD80 deleted of its intracellular 
domain fails to recruit CD28, CTLA-4 and PKCe to the synapse. Tseng et al. 
have suggested that cosignaling molecules such as CD80 may function to 
segregate CD28 and CTLA-4 away from the TCR creating a distinct 
costimulation zone in the IS, near the boundary between the cSMAC and the 
pSMAC, a zone dependent on cytoskeletal integrity. 
1.3.8 The IS directs T cell differentiation 
A phase of sustained signaling is crucial in supporting the commitment of 
activated T cells to full effector potential (144, 157). Early after activation, CD4 
cells secrete IL-2 and are designated ThO cells. Depending on the nature of the 
cytokines present at the site of activation, ThO cells will go down one of two 
major differentiation pathways: Th1 or Th2. Th1 cells secrete Th1-type cytokines 
including IFN-y and TNF-p and are important in inducing cell-mediated 
immunity. Th2 cells secrete Th2-type cytokines such as IL-4, IL-5, IL-9, IL-lO 
and IL-13 and are efficient at inducing humoral immune responses. T cell 
differentiation is established and maintained via the action of lineage specifie 
transcriptional regulators induced by these cytokines. The Th! specifie 
transcription factor is T -bet while the Th2 subset specifie transcription factor is 
GATA-3 (158). Apart from their different functions, effector cells express 
partially different sets of receptors specifie for inflammatory chemokines that are 
required for migration to peripheral sites in contrast to naïve T cells that express 
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the lymph node homing CCR7 receptor (159). It appears that the IS serves as a 
platform for 'cytokine presentation' from DC to naïve T cells (157). Strong TCR 
signaling as been shown to lead to IFNy receptor (157) IS polarization and the 
assembly of a Th1 signalosome further stabilized by the subsequent secretion of 
IFNy (160). If IL-4 is delivered, an inhibitory signal prevents polarization, 
implying that the Th1 pathway may be the default response of the ThO. Parallel 
engagement of TCR and IL-4 receptor might then lead to assembly of a Th2 
signalosome (161). 
1.4 Cosignaling 
Cosignaling molecules govern the functional outcome of the TCR signal (162) by 
modulating large sets of genes also modulated by TCR signaling, and only 
exceptionally induce specific genes such as IL-2 (75). Cosignaling requires a 
cascade of complex interactions (75). Cosignaling molecules can be co-activators 
or co-inhibitors. The relative contribution of these co-signaling molecules during 
different phases of the immune response is possible because of their temporal, 
spatial and functional separation. The cosignaling molecules are cell surface 
glycoproteins and are divided in two major groups: the immunoglobulin 
superfamily (IgSF; that inc1udes the CD28, the B7 and the SLAM families) and 
the tumor-necrosis factor (TNF) superfamily. Recently, several proteins have been 
identified as new members of the IgSF or the TNF cosignaling superfamily. These 
new members appear to differ from the conventional pathways and from each 
other based on their expression patterns and differential effects on individual 
lymphocyte subsets. The work presented in this thesis focuses on the CD80 and 
CD86 cosignaling molecules important for naïve CD4 T cell activation. A brief 
overview of the newly identified cosignaling molecules is presented. 
1.4.1 Ig superfamily 
The IgSF is one of the largest in vertebrates' genomes. Significantly, the increase 
in IgSF numbers from invertebrates to vertebrates parallels the evolution of the 
adaptive immune system (163). The presence of a single exon co ding for most 
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IgSF domains provided the genetic basis for duplication and diversification that 
gave rise to this large family of proteins. IgSF domains can be c1assified as IgV, 
IgC1, IgC2, or Igl according to their primary sequence and overalliength (164). 
These domains all present the characteristic Ig fold of antiparallel beta strands 
arranged in two sheets linked by a disulfide bond (165) as shown in figure 4. This 
disulfide bond is not essential for the domain structure and IgSF pro teins lacking 
this disulphide have been reported (166). 
Figure 4 The Typical Ig Fold (adapted from (166» Ig domains all present the 
characteristic Ig fold of antiparallel beta strands arranged in two sheets linked by a 
disulfide bond (between strands B and F). The front face is composed of 
GFCC'C" strands and the back sheet is composed ofthe ABED strands. 
The 'variable' (lgV) domains of immunoglobulins contain their antigen-binding 
properties and the 'constant' (lgC) domains mediate their effector functions. IgC 
domains are shorter than IgV domains as they lack strands C' and C" within the 
Ig fold. Domains showing similarity to overall IgV domain sequences are 
referred to as IgV-like. However, although IgV-like domains show sequence 
similarity to the immunoglobulins variable domains, they do not present the 
variability that characterize antibody molecules. Domains with sequence patterns 
more similar to IgV but more of the size of IgC domains are called IgC2 domains 
and the classic IgC domains, found almost exclusively in Ig, MHC antigens and 
J32M, are referred to as IgCl. 1 set domains are intermediate between those of V-
and C-set domains, in agreement with the suggestion that 1 set domains are the 
ancestral family. Evans et al. (167) recently proposed that IgV domains be 
subdivided into IgVI and IgV2 domains to reflect structural differences between 
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IgV typical of antigen receptors and those of adhesion molecules. Hallmarks of 
antigen receptor IgV domains are the substantial beta strand A and B interactions 
and C' - and G-strand p-bulges, rather than the limited A' -G contacts and the p-
bulges located immediately after C' - and G-strand of adhesion molecule IgV. 
The majority of proteins with Ig domains are type 1 membrane proteins with a 
single transmembrane region although secreted and cytosolic IgSF proteins exist. 
About 33% of the molecules at the surface ofhuman leukocytes are IgSF proteins 
and of these, half present an IgV-IgC2 domain organization (166). Cytoplasmic 
regions of IgSF proteins vary in length and many have recognizable motifs for 
signaling such as IT AM and ITIM (!mmunoreceptor !yrosine-based inhibititory 
motif) and regions that interact with adaptor proteins and cytoskeletal 
components. In many cases the IgV domain contains the binding specificity and 
although antibodies bind molecules with high affinity, most proteins containing 
IgSF domains have weak interactions such as MHC peptide antigen recognition 
by the TCR (70). The interactions usually involve a single Ig domain even if the 
other domains are most probably necessary to maintain the orientation of the 
binding site and the optimal distance from the membrane. Ig domains are 
glycosylated at various extents and since N-linked carbohydrates are almost as big 
as Ig domains, glycosylation represent a major feature of these proteins. The 
attached carbohydrates can restrict the movement of these membrane proteins and 
hence optimize their binding to receptors of opposing cells. Cosignaling proteins 
belonging to the IgSF can be further divided in three subfamilies, namely, the 
CD28 family, the B7 family and the SLAM/SAP family. 
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Lymphoid organ Periphery 
Figure 5 Cosignaling Molecules (adapted from (75» This diagram depicts the 
multitude of cosignaling interactions that occur both in lymphoid organs and in 
the periphery. Only CD28 and HVEM and their counter receptors are involved in 
the initial T cell activation by professional APC in lymphoid organs. The 
CD28/CTLA-4: CD86/CD80 (B7) interactions are the focus of this thesis. T cells 
in a state of progressed activation utilize a multitude of cosignaling molecules 
such as CD28, lCOS, OX40, 4-1BB, CTLA-4 and PD-l while interacting with 
professional APC. The relative importance ofthese various cosignaling molecules 
will change depending on local requirements. Most of the newly identified 
cosignaling molecules function in later stages of T cell activation and sorne in the 
periphery. 
1.4.1.1 The CD28 family 
CD28 was the first cell surface molecule identified as a costimulatory receptor 
(168). The CD28 family is composed of 2 co-activators (CD28 and lCOS -
inducible costimulator-) and 3 co-inhibitors (CTLA-4/CDI52 -cytotoxic T 
lymphocyte-associated antigen 4-, PDI -programmed death 1- and BTLA -B and 
T lymphocyte attenuator-) that share 23 to 30% homology to CD28 (92). Figure 5 
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displays C028 members, their counter-receptors and their expression sites. C028 
counter receptors belong to the B7 cosignaling protein family. 
1.4.1.1.1 Structure and gene localization of the CD28 
family 
Members of the C028 family are type 1 transmembrane proteins generally 
expressed on T lymphocytes and present one extracellular IgV domain and a short 
intracellular domain that contain motifs important for signaling. C028, ICOS, and 
CTLA-4 are clustered in close proximity on chromosome 2q33 and have an 
unpaired cysteine that allows them to homodimerize on the T cell surface (169) in 
contrast to POl and BTLA that are located in distinct locations in the human 
genome (2q37 and 3q13, respectively) and that do not homodimerize. N-
glycosylation has also been shown to be required for CTLA-4 dimerization (170). 
1.4.1.1.2 Expression patterns of CD28 family members 
C028 is constitutively present on >90% ofhuman C04 T cells and 50% ofhuman 
C08 T cells but is constitutive on all murine T cells. C028 costimulation is 
necessary for the initiation of most T cell responses and blockade of C028 
signaling results in ineffective T cell activation. ICOS is induced following T cell 
activation and expressed by effector T cells. Resting T cells express very low 
levels of CTLA-4 and its expression levels are kept very low even on activated 
cells (151). CTLA-4 has a 30- to 50-fold lower surface density than C028 (171). 
CTLA-4 is stored in intracellular vesicles (172) and undergoes complex 
intracellular trafficking mediated by binding to the clathrin-adaptor molecules 
AP-1 and AP-2. However, CTLA-4 is constitutively expressed in the 
C04+C025+ Treg subset (173). BTLA is found on activated but not naïve T 
cells. The co-inhibitory receptor POl is only expressed on activated T cells and 
exerts its main function in the periphery. 
1.4.1.1.3 Knockout models of the CD28 family members 
In C028 knock-out mice, T cell differentiation appears normal but show strongly 
impaired T cell and B cell responses due to the lack of B7 mediated cosignaling. 
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The critical role of CTLA-4 as a negative regulator of T cell activation is 
dramatically illustrated in CTLA-4-deficient mice, which die from massive 
lymphocytic infiltration and tissue destruction in critical organs (174, 175). Mice 
expressing only the extracellular domain of CTLA-4 show lymphadenopathy but 
are spared from the massive lymphoproliferation illustrating the importance of 
CTLA-4 intracellular domain for its function (176). The ICOS pathway appears to 
play a critical role in humoral immunity since ICOS deficient mice have 
decreased serum IgG levels and show defects in isotype switching and germinal 
center formation (177). PD1 knock-out animaIs suffer from a phenotype similar to 
CTLA-4 knock-out mice with lymphocyte infiltration in tissues although disease 
severity is different (178). BTLA deficient mice present enhanced immune 
responses (179). 
1.4.1.1.4 Structure and function of CD28 and CTLA-4 
CD28 and CTLA-4 are the major regulators of TCR engagement in naïve T cells. 
CD28 (168, 180) and CTLA-4 (180, 181) were c10ned in 1987. Both are obligate 
homodimers due to their interchain disulphide linkage (180). Interestingly, both 
the transmembrane and intracellular region of CTLA-4 are required for 
homodimer formation (182). CTLA-4 dimerization is also dependent on N-
glycosylation (170). Approximately 25% of the residues are rigorously conserved 
between CD28 and CTLA-4 and conservation of surface residues in CD28/CD152 
is essentially limited to the CD80/CD86 binding site located in their CDR3-like 
regions (183). A key surface plasmon resonance study from Collins et al. (184) 
established that CTLA-4 is a bivalent homodimer and CD28 is a monovalent 
homodimer, a finding confirmed in the crystal studies of both molecules (167, 
185, 186). Recent studies have described a CTLA-4 molecule that can exert 
inhibitory functions independent of CD80 and CD86 binding (187). 
1.4.1.1.5 CTLA-4 solution study 
ln 1997, Metzler et al (188) reported the solution structure of CTLA-4 obtained 
by NMR spectroscopy (figure 6). The structure of the extracellular domain of 
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CTLA-4 consist oftwo p-strands, the ABED and A'GFCC' strands connected by 
the canonical Ig sulfide bond and an additional non-Ig sulfide bond. CTLA-4 
extracellular contains two N-linked glycosylation sites. The conformation of the 
MYPPPY loop extends the A'GFCC' face by making the beta sheet surface flatter 
providing a large accessible surface suitable for binding interactions (188). 
Crystal studies of the CTLA-4 receptor bound by its two ligands have also been 
reported and are discussed in another section (185, 186). 
+-CDR3 
Figure 6 Ribbon Diagram of CTLA-4 Extracellular Domain (from (188» Ribbon 
diagram depicting CTLA-4 secondary structure: beta strands A, A', B, C, C', D, 
E, F, G form two p-pleated sheets (front face A'GFCC' and back face ADEB) 
that adopt a p-sandwich configuration. The CDR1 region and CDR3 region are 
indicated while the disulfide bonds are shown in ball stick representations. 
1.4.1.1.6 CD28 crystal 
In 2005, almost 20 years after its original description (168), Evans et al. (167) 
reported the crystal structure of the extracellular region of CD28 in complex with 
a Fab (fragment antigen binding) fragment. As shown in the surface 
representations in figure 7, the structure of monomeric CD28 resembles that of 
monomeric CTLA-4 since the ligand binding faces of both monomers bear 
similarities, inc1uding the conserved MYPPPY loop. However, notable structural 
differences are also observed. The dimer interface of both molecules show 
differences that prevent the formation of CTLA-4/CD28 heterodimers consistent 
with the failure to detect such heterodimers. Importantly, CD28 and CTLA-4 
show great difference in the orientation of their monomeric subunits relative to 
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CD80 and CD86 binding. In contrast to CTLA-4 IgV domains that are arranged in 
a 'V' structure, IgV domains of CD28 are arranged in a oU' structure. Although 
both arms are available for ligand binding, simultaneous binding of separate 
monomers is prevented by a physical clash of the IgC of CD80 and CD86. Even if 
direct physical clashes may not completely prevent bivalent binding, occupancy at 
one site would reduce the 'on rate' for binding at the second site by about 86% 
(167). Therefore the CD28 molecule can only bind to monomeric forms of its 
ligands. 
Figure 7 CD28 and CTLA-4 Molecules (adapted from (167) Surface representations 
of the putative CD28 homodimer observed in the crystal lattice (left) and the 
native CTLA-4 homodimer (right). The ligand-binding surface of CD28 is in dark 
gray and the equivalent surface in CTLA-4 is light grey. Glycosylation sites in 
each protein are shown as punctual grey sites. The C termini (and the T cell 
surface) are toward the top. Of note, the arms of CD28 form more of a oU' 
structure while CTLA-4 arms form more of an open 'V' conformation. 
1.4.1.1. 7 MYPPPY motif 
As previously noted, the most notable conservation of amino acids between CD28 
and CTLA-4 not including IgSF consensus residues is the hexapeptide MYPPPY 
sequence motiflocated in the IgV domains ofboth CD28 and CTLA-4 (183). The 
hexapeptide hydrophobie motif MYPPPY is located to the FG loop, that is, in the 
CDR3 analogous region. More specifically, this motif mediates CTLA-4 and 
CD28 binding to CD80 and CD86 and the high conservation of this motif can 
certainly explain why interactions between CD28 and B7 family proteins are 
detectable across species after 300 million years of divergent evolution. As 
expected from typical IgV domains, CD28 and CTLA-4 CDRI and CDR3 regions 
are closely apposed in the membrane while the CDR2 region does not interact 
directly with the counterreceptor. Solvent exposed CDR3 regions on antibody 
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structures form a major component of the antigen recognition site (189) and parts 
of these loops are also important binding determinants in the CD8-MHC c1ass 1 
interaction (31, 32) and in the CD4-MHC c1ass II interaction (33,34). Mutation of 
any of the MYPPPY residues in CTLA-4 or CD28 leads to reduced binding of 
CD80 or CD86 (183, 190-192). Results show that, although the same overall 
region on CD28 and CTLA-4 is involved in the interactions with CD80 and 
CD86, subtle but important differences in ligand recognition exist between the 
twO molecules. Altogether, the MYPPPY motif is involved in differential, as well 
as common, recognition of the counter-receptors (192). The contacts between 
CD80 and the CTLA-4 MYPPPY motif are shown in figure 8. 
Figure 8 MYPPY Motif in CTLA-4:CD80 Interaction (adapted from (185» The 
MYPPPY loop of CTLA-4 (shown on the left side) is buried in a shallow 
depression of the CD80 GFCC' surface (shown on the right side). Hydrogen 
bonds are formed across the p-sheets ofthe interacting proteins. 
1.4.1.1.8 CD28 and CTLA-4 signaling 
CD28 and CTLA-4 signaling takes place within the IS (150, 155, 193). Signaling 
via both the TCR and CD28 results (194, 195) in rearrangements of membrane 
and cytoskeletal components, MTOC (micro!ubule Qrganizing çenter) 
reorientation, accelerated intracellular vesic1e trafficking, activation of 
transcription factors, accumulation of lipid rafts in the IS, high leve1s of IL-2 
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cytokine and survival signaIs (194). CD28 lowers the threshold for T cell 
activation by decreasing the number of ligated TCR that is required for a given 
biological response (79). The unique function of CD28 resides in its ability to 
induce IL-2 in naïve T cells (75). Mutational analysis of the CD28 cytoplasmic 
tail indicates that induction of cytokines and control of cell survival are regulated 
by distinct domains within the CD28 cytoplasmic tail. On the other hand, CTLA-4 
engagement selectively blocks augmentation of genes regulated by CD28-
mediated co-stimulation, but does not ablate gene regulation induced by TCR 
triggering alone (196). CTLA-4 inhibition of T cell activation can occur by 
various mechanisms (reviewed in (151)) such as out-competing CD28 for binding 
to B7 proteins due to its higher affinity for them (184), by forming periodic 
structures with its ligand that could interfere with the IS (185, 186, 197), by 
inducing immunosuppressive cytokines and/or by promoting the assembly of 
inhibitory signaling complexes antagonizing TCR and CD28 signaling. 
1.4.1.2 B7 family 
In contrast to the CD28 family members that were discovered by their functional 
effects, most of the B7 family member ligands were discovered by homology 
searches that revealed many proteins resembling CD80 and CD86, the founding 
members of this family. Sorne of these newly identified molecules are not 
recognized by any of the known receptors for B7 molecules. Because this thesis 
focuses on the classical B7 proteins CD80 and CD86, a brief introduction to other 
B7 is given and CD80 and CD86 are discussed in a separate section. Figure 6 
shows sorne B7 members, their counter receptors and expression sites. 
1.4.1.2.1 Structure of the B7 family members 
The genetic linkage of B7-related molecules to the MHC has been noted 
previously (198). Two or four extracellular Ig-like domains in a IgV/IgC order 
characterize the B7 family members. The B7 family consists of 4 co-activators 
(CD86, ICOS-LIB7H2, PDL21B7DC, B7H3) and 4 co-inhibitors (CD80, 
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PDL11B7H1, B7H41B7x, B7H3) although studies are still clarifying the exact role 
of sorne of these molecules. 
1.4.1.2.2 Expression of the B7 family members 
B7 proteins are generally expressed on APC although they can be expressed on 
other cells. CD80 and CD86 are expressed mainly on APC with different 
expression kinetics. CD80 and CD86 expression on T cells has also been reported 
and may play a role in lymphocyte homeostasis (91). In general, co-activatory 
(co-stimulatory) molecules are constitutively expressed at low levels and rapidly 
upregulated upon receiving various inflammatory stimuli while co-inhibitory 
molecules expression is induced. ICOS-L is expressed on B cells, monocytes, iDC 
but not mDC. DC and macrophages express B7DC. T and B cells express B7H1 
and mRNA can be found in various human tissues; however its expression 
requires exposure to inflammatory cytokines such as IFN y. B7H3 mRNA is 
expressed in both lymphoid and non-Iymphoid tissues. Both an inhibitory and 
stimulatory function for B7H3 has been suggested although studies in knockout 
mice support an inhibitory function for this molecule (199). B7H4 mRNA is 
detected in many tissues but the protein is not expressed in normal cens 
suggesting a post-translational control mechanism. B7H4 might have a role in the 
regulation of the early phases of immune responses during inflammation in 
peripheral tissues (92). 
1.4.1.3 The SLAM/SAP family 
Based on their sequence homology, the SLAM family is part of a broader 
subgroup ofIg-like receptors referred to as the CD2/SLAM family (200-202). The 
genes coding for the CD2/SLAM family are an encoded on human chromosome 1 
except for the sap gene that is encoded on the X chromosome. AH members of 
the SLAM family are composed of an extracellular domain formed of two or four 
Ig-like domains that include aN-terminal IgV domain without disulphide bonds 
and a IgC2 domain with 2 putative disulphide bonds. SLAM proteins also present 
an intracellular domain that contains tyrosine motifs. SLAM receptors are 
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expressed in a variety of immune cells and function at the IS. Ligand binding 
induces their interaction with adaptor molecules SAP (SLAM -associated protein) 
and/or EAT2 proteins and signaling that recruits and activates several SRC 
kinases. This signaling is believed to fine tune cell activation mediated by TCR 
and cosignaling molecules. SignaIs mediated by the SLAM receptors can also 
affect the function of APC (200). 
1.4.2 TNFRlTNF family 
Figure 6 shows sorne TNFR members, their counter receptors and expression 
sites. Apart from CD40 that plays a crucial role in immune responses initiation, 
members of the TNFRlTNF family can influence T cell responses in various ways 
(203). TNFR family members have a major role in T cell survival following 
CD28-B7 cosignaling. As reviewed in (203), TNFR family members are type 1 
transmembrane proteins characterized by extracellular cysteine-rich motifs and 
fall into three groups (203): 
(1) DD (Death domains)-containing receptors (such as Fas/CD95) that 
activate caspase cascades leading to apoptosis 
(2) Decoy receptors 
(3) TRAF (TNF receptor-associated factor) binding receptors that lack DD 
but contain TRAF recruitment motifs 
TNFR ligands are type II cell surface glycoproteins (203). Knock-out mice show 
no drastic phenotype but show T cell survival impairments (203). TNFR 
c1ustering by trimeric TNF ligand leads to TRAF aggregation and their interaction 
with downstream signaling molecules mediating important downstream events 
such as survival, cellular proliferation and cytokine secretion (203). All 
costimulatory members of the TNFR family have the ability to recruit TRAF2 but 
differ in their recruitment of other TRAF proteins. Henceforward is a brief 
overview of sorne TNFR pairs that affect initial T cell activation. The 
CD27/CD70 pair is expressed on T cells and their ligands are induced soon after 
activation suggesting a function early after TCRlCD28 signaIs as seen with the 
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HVEMILIGHT pair (203). The 4-1BB (CD137)/41BBL pair has been shown to 
have preferential effects on CD8 T cells costimulation in sorne models while the 
OX40 (CD 134)/OX40L pair shows preferential effects on CD4 T cells (203). 
1.4.2.1 CD40: A TNFR tbat acts as a major switcb for T cell 
cosignaling 
CD40 is important in both cell mediated and humoral immunity. CD40 is as a 
master switch for T cell cosignaling as it regulates the upregulation of 
costimulatory molecules and adhesion molecules important in the initiation of 
immune responses on APC (204). CD40 is a membrane glycoprotein expressed on 
B cells, DC, macrophages, epithelial cells, hematopoietic pro genitors , and 
activated T cells. !ts ligand, CD154 (CD40 ligand), is a type II integral membrane 
protein expressed on activated T cells, activated B cells, and activated platelets. 
CD40 function is dependent on several different structural motifs in its 
cytoplasmic domain. Moreover, an extracellular Cys residue has also been 
implicated in sorne CD40 functions by allowing dimer formation (205, 206). 
CD40- and CD 154-deficient mi ce show phenotypes that are quite similar to each 
other implying an exclusive receptor-ligand pair (204) and revealed the 
importance of these molecules in humoral memory as their deficiency leads to 
defects in B cell isotype switching, B cell migration and germinal centers 
development. 
1.4.3 Cosignaling superfamily crosstalk 
Two recent studies (207, 208) have provided a new perspective in this already 
complex area by describing the unexpected interaction between the 
immunoglobulin family member BTLA and the TNFR family member HVEM. 
Not only does these studies show crosstalk between two distinct cosignaling 
superfamilies, they describe the interaction of a co-activating and a co-inhibiting 
receptor (209). The crystal structure of this interacting pair has been determined 
(210). Although HVEM is believed to transmit a positive cosignal in T cells upon 
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binding ofits TNF ligand LIGHT, binding to BTLA has been suggested to induce 
negative signaling resulting in T cell proliferation inhibition (207, 208). 
Major questions remain with respect to signal integration generated by the various 
cosignaling pairs. Studies involving mice lacking more than one receptor or 
ligand might prove useful in determining the interplay between these molecules. 
A model of T cell activity integrating the cosignaling function of both 
superfamilies could certainly aid in the understanding of how lymphocyte 
differentiation is specified, effector cells regulated, memory generated, and 
tolerance maintained (78). 
1.5 CD80 and CD86 
CD80 and CD86 (also known as B7-1 and B7-2; sometimes referred to as the B7) 
are the only functional ligands of CD28 and CTLA-4. Despite sorne structural 
similarities and common binding partners, different functional properties have 
been attributed to CD80 and CD86. These different biological properties emanate 
from different patterns of expression that mimic that of CTLA-4 and CD28 
respectively, different signaling pathways, different binding properties and 
differences in molecular organization. 
1.5.1 Genomic organization of CD80 and CD86 
CD80 and CD86 were identified in 1989 and 1993 respectively (211-213). Both 
human and murine CD80 genes were cloned by Freeman et al. (212,214) and the 
human and murine CD86 genes were cloned by Freeman et al. (211, 215) and 
Azuma et al. (213). The human cd80 gene (3q13.3-q21) is composed of six exons. 
Exon 1 is not translated. The second exon contains the initiation codon and 
encodes a signal peptide. The third and fourth exons correspond to the IgV and 
IgC domains. The fifth and sixth exons encode respectively the transmembrane 
portion and the cytoplasmic tail (216). The human cd86 gene (3q21) has eight 
exons (217). Exons 1 and 2 contain the untranslated region. Exon 3 codes for the 
signal peptide. Exons 4 and 5 encode the IgC and the IgV domains. Exon 6 
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encodes the transmembrane domain and exon 7 and 8 encode the cytoplasmic 
domain. The close relationship between exons and functional domains is a 
characteristic feature of genes of the IgSF. CD80 and CD86 are believed to have 
arisen via duplication of a common precursor. The preservation of both genes in 
aIl mammals strongly suggests that they have been subjected to distinct selection 
pressures. Alternative splice variants have been described for both CD80 and 
CD86 (218-222). Mice deficient in CD80 and CD86 have si gnificant 
abnormalities in both humoral (including Ig class switching and germinal center 
formation) and cellular immune responses suggesting considerable overlap in the 
cosignaling functions of CD80 and CD86 (223). 
1.5.2 IgSF domain description of CD80 and CD86 
CD80 and CD86 are type 1 membrane proteins of 60kDa and 80kDa respectively. 
They are members of the IgSF. As shown in figure 9, their extracellular regions 
consist of two anti-parallel ~-sandwich IgSF domains (membrane distal IgV and 
membrane proximal IgC) joined by a short linker region. As with other IgSF 
members, Ig V and IgC from CD80 and CD86 present front and back sheets 
composed of AGFCC'C" and BED strands, respectively. Despite their common 
receptors the extracellular regions of human CD80 and CD86 share only ~25% 
sequence identity. An early study from Bajorath et al. (224) used a topological 
fingerprint method to compare CD80 and CD86 to other known IgSF proteins. 
The B7 IgV domains were shown to include sorne structural features that departed 
from currently known Ig folds. In contrast, the IgC domains displayed significant 
sequence compatibility with IgC structures and were best matched to ~2m IgC 1 
suggesting that the B7 IgC region, like ~2m, might be involved in protein-protein 
interactions perhaps with the N-terminal IgV domain or, alternatively, with other 
moleeules. CD80 and CD86 are both glyeosylated (213) and N-linked 
glycosylation sites in the IgV and IgC domains are localized to regions opposite 
to the receptor interaction site. Extensive glycosylation of CD80 and CD86 may 
aid in solubility since the extracellular domains contain a number of hydrophobie 
residues. CD80 and CD86 intracellular domains present 27 and 63 amino acids 
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respectively. CD86 presents three predicted PKC phosphorylation sites and CD80 
is believed to be linked to the cytoskeleton via its intracellular domain (225, 226). 
Figure 9 Ribbon diagram of CD80/CD86 (adapted from (227» CD80/CD86 
extracellular IgV and IgC domains consist of two anti-parallel B-sandwich IgSF 
domains joined by a short linker region. Glycosylation sites are shown in ball-
stick representations. 
1.5.3 CD80 and CD86 expression 
CD80 and CD86 expression is tightly regulated at the APC surface. CD86 is 
expressed constitutively at low levels and is rapidly upregulated following T cell 
encounter and maximally expressed around 24h, whereas CD80 is expressed later 
after activation and is stable for a longer period of time (228, 229). The different 
expression patterns of CD80 and CD86 suggest distinct interactions with CD28 
and CTLA-4. Indeed, CD28 and CD86 are present earlier on the cell surface 
compared to CD80 and CTLA-4. Therefore CD28:CD86 interaction is believed to 
play a pivotaI role in the activation of naïve T cells whereas CD80:CTLA-4 plays 
a major role in terminating T cell responses. Apart from APC expression, CD80 
and CD86 can be expressed on T cells; this proteins expression may be important 
for in vivo T cell homeostasis (91). 
1.5.4 CD80 and CD86 signaling in APC 
CD80 and CD86 binding to CD28 and CTLA-4 induces T cell signaling. 
However, many studies have also shown that CD28 and CTLA-4 binding to 
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CD80 and CD86 proteins delivers signaIs in APc. Binding of CD28 to CD80 and 
CD86 Ieads to IL-6 production by DC, resulting in an increased 
immunostimulatory activity (230). On the other hand, binding of CTLA-4 to 
CD80 and CD86 proteins induces IFNy, which, in turn, up-regulates the 
expression of the IDO (indolamine 2,3-dioxygenase) enzyme resulting in 
tryptophan catabolism and T cell proliferation suppression and apoptosis (94, 
231). These signaling cascades are dependent on the simultaneous expression of 
CD80 and CD86. 
In accord with the predicted preferential receptor interaction (184), CD86 cross-
linking up-regulates B cell proliferation, enhances the expression of antiapoptotic 
molecule Bel-xL and stimulates the production of IgG 1, IgG2a, and IgE (232, 
233). In contrast, cross-linking of CD80 on B cells leads to reduced proliferation 
and up-regulation of proapoptotic molecules caspase-3, caspase-8, Fas, FasL, 
Bak, and Bax (233, 234). A recent study showed that CD86 induced signaling in 
activated B cells increased the activity of PI3K and the phosphorylation of PKC 
and lkB thereby modulating B cell gene expression and activity (235). It is 
interesting to note that 'reverse signaling' has also been described for other B7 
family members such as B7DC (236-238). Crosslinking of B7DC on DC by 
pentameric IgM antibodies leads to the activation of DCs, which subsequently 
enhances their ability to stimulate T ceIls; interestingly B7DC has only one 
intracellular amino acid (239). Signaling within the APC might be an important 
feedback mechanism for the regulation of T ceIl: APC interactions (240). FinaIly, 
covalent receptor dimerization and counter receptor multimerization are two key 
features of the CD28/CTLA-4/CD86/CD80 interaction system that may regulate 
signal transduction by controlling the duration of receptor occupancy. 
1.5.5 CD80 and CD86 binding data 
Our understanding of CD80 and CD86 function is supported in part by knowledge 
of their affinity and binding kinetics to CD28 and CTLA-4 (241). The Kd 
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(equilibrium dissociation constant) values and interaction properties of CD80 and 
CD86 with their receptors are shown in figure 10. Both CD80 and CD86 show 
higher affinity for CTLA-4 than to CD28 with a difference of at least 10-fold 
(214). CTLA-4 covalent dimerization is required for its high binding avidity even 
if each monomeric subunit contains a binding site for CD80/CD86 (182). It has 
been suggested that binding of the first B7 molecule to CTLA-4 reduces the on-
rate for binding of the second (184). The Kd of CD80 binding to CD28 is 4uM 
and that ofCD80:CTLA-4 is ofO.2uM (242, 243). The Kd value ofCD86 binding 
to CD28 is of 20uM and that of CD86:CTLA-4 is of 2.6uM (242, 243). CD86 
shows faster on and off rates to CTLA-4 when compared to CD80 (241, 243). 
Earlier studies had emphasized the similarities in CD80 and CD86 binding 
properties. However, the CD80 and CD86 proteins used in these studies were 
multivalent biasing the results (191, 241). The interaction properties of the 
CD281B7 system were clearly established in a key biacore study from Collins et 
al. (184). In this study, CD80 behaved as a homodimeric ligand in contrast to 
CD86 that behave as a monomeric ligand. The general conclusion of these 
findings showed that CD80 is the preferential ligand of CTLA-4 and CD86 is the 
preferential ligand for CD28. Compared to CD28:CD86 and CTLA-4:CD80 
complexes, CD28:CD80 and CTLA-4:CD86 complexes are believed to be of 
intermediate strength since CD28 is monovalent and CD86 does not self-
associate. Importantly, these results are in agreement with findings of Pentcheva-
Hoang et al. (155) that showed, using APC deficient in either CD80 or CD86, that 
while CD80 favors binding to CTLA-4, CD86 shows a preference for CD28 in the 
context of the IS. The interaction hierarchy with initial engagement of CD86 by 
CD28 followed by engagement of CD80 by CTLA-4 appears to have evolved in 
such a way that weak interactions are sufficient to trigger T cell activation while 
much stronger interactions are required for attenuation, thereby pro vi ding an 
intrinsic mechanism for modulating T cell responses. The CD28:CD86 interaction 
has similar properties to TCR and adhesion molecule ligand interactions; i.e., 
binding is monovalent and has fast kinetics and similarly high Kd values (244, 
245). Interactions with these properties are ideally suited for dynamic cellular 
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contacts, facilitating the "scanning" of cellular targets for antigens and adhesion 
molecules early in immune responses. The switch between monovalent and 
bivalent binding is likely to have had the largest single effect on the relative 
strength of these interactions. A structural change of this type could have initiated 
the functional diversification ofthis signaling system (184). Very interestingly, a 
recent report (246) shows that CD28 monovalency is essential for cosignaling. In 
this study, a chimeric bivalent CTLA-4 (extracellular)/CD28 (intracellular) 
protein could bypass the need for TCR co-engagement for signal initiation. 
Therefore CD28 monovalency impacts the autonomy ofthis receptor and only the 
combination ofTCR and CD28 ligation can lead to full T cell activation. 
APC 
T cell 
87-2: 87-1: 87-2: 87-1: 
CD28 CD28 CTLA-4 CTLA-4 
Kd 20 4 2.6 0.2 
(J.1M) 
Figure 10 Interaction Properties of CD80/CD86 and CD28/CTLA-4 (adapted 
from (184» Binding properties ofhuman CD28, CTLA-4, CD801B7-1 and CD861B7-
2 and their respective Kd values. The predicted binding properties are as follows: 
CD28 is a monovalent homodiner; CTLA-4 is a bivalent homodimer; CD801B7-1 
is a monovalent homodimer; CD861B7-2 is a monovalent monomer. 
1.5.6 CD80 and CD86 Ig domains in their binding properties 
Many studies have addressed the role of CD80 and CD86 Ig like domains in 
receptor binding. A pioneer mutational analysis study from Peach et al. (247) 
identified conserved residues within the IgV domains ofboth CD80 and CD86 to 
be critical for binding to CTLA-4 and CD28. Il hydrophobie residues within the 
IgV domain of CD80 were shown to be critical in receptor binding. The identified 
residues mapped to the GFCC'C" front face ofthe IgV fold, the same face known 
to mediate interactions in other IgSF members (248, 249). Mutagenesis of 
62 
corresponding residues in CD86 established that sorne, but not all, of these 
residues also played a role in CD86 receptor binding. IgC domain deletion also 
differentially affected CD80 and CD86 binding to their receptors. CD80 IgC 
deletion completely abrogated receptor interaction (247) and a mutational study 
from Guo et al. (250) identified several amino acids in loops between strands B, 
C, D and E of the IgC to be important for CD80 interaction with CTLA-4/CD28. 
Freeman et al. (251) and Rennert et al. (252) also pointed to the importance of 
CD80 and CD86 IgC domains. Domain-specific constructs of human CD80 and 
CD86 revealed that CD80, CD86 and the IgV domain of CD86 bound to CTLA-4 
and CD28 in contrast to CD80 IgV domain, the CD80 IgC domain and the CD86 
IgC domain that were unable to bind CD28 nor CTLA-4. Fargeas et al. (253) not 
only identified IgV residues W84 and Y87 as being critical for CD28 and CTLA-
4 binding, they also showed that mutations at conserved residues within the IgC 
domain of CD80 lead to a defect in CD28 and CTLA-4 binding (253). 
Agadjanyan et al. (254) also focused on the domain structure of these molecules 
by studying chimeric and deleted forms of CD80 and CD86 molecules. CTL 
responses against the HIV env glycoprotein when coinjected with the various 
forms of CD80 and CD86 were studied. Dramatic improvement in in vivo 
costimulation was observed after removal of the IgC of CD80. Moreover, the 
chimeric molecule expressing the IgV domain of CD80 and the remaining of 
CD86 enhanced T cell activation. These data showed the importance of CD86 IgC 
domain in T cell activation. Vasu et al. (255) further deepened the understanding 
of the role of IgC domains of CD80 and CD86 by preparing chimeric constructs 
in which the IgC domains of human CD80 and CD86 molecules where swapped. 
The cosignaling function of these chimeric molecules was assessed in CHO cells. 
Like CD86, the V80C86T80 chimera showed a substantial increase in T cell 
activation relative to CD80; in contrast, relative to CD86, V86C80T86 diminished 
T cell activation. Altogether, these studies show that both IgV and IgC domains 
are crucial for CD80 and CD86 function. 
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1.5.6.1 CD80i\C 
It is interesting to note that a naturally occurring CD80 splice variant lacking the 
IgC was observed. This splice variant was first described by lnobe et al. (221) in 
1994 in LPS stimulated C57BL/6 mice splenic B cells by RT-PCR. Moreover, by 
analyzing B7 expression in a number of different celllines by PCR, Guo et al. 
(250) also reported this alternatively spliced CD80 lacking the IgC domain. In 
contrast to the Inobe study, this alternatively spliced form had lost its binding to 
both CD28 and CTLA-4. These results are in accord with the Peach et al. (247) 
findings that showed that the absence of CD80 IgC domain resulted in a 10-fold 
reduced binding to both CTLA-4 and CD28. 
1.5.7 Crystal studies ofligated CD80 and CD86 
As suggested by earlier mutational studies, crystal studies (185, 186) showed the 
crucial importance of the IgV front faces ofboth CD80 (shown in figure 11) and 
CD86 (shown in figure 12) in interacting with CTLA-4. The binding interface is 
formed by packing interactions between the front sheets of each molecule. The 
AGFCC'C" face forms a shallow concave surface that accommodates binding of 
the MYPPPY loop. The CTLA-4 FG loop that contains the MYPPPY motif 
makes hydrophobic contacts and five hydrogen bonds with a largely nonpolar 
surface of CD80 consisting of Tyr 31, Met 38, Thr 41, Met 43,Val 83, Leu 85, 
Ala 91, Phe 92 and Leu 97. At the core of the interface, Pro 102 ofCTLA-4 and 
Tyr 31 of CD80 participate in a stacking interaction. The CTLA-4/CD86 interface 
is also stabilized by five hydrogen bonds and van der Waals contacts and the 
hydroxyl group of CTLA-4 Tyr-100 forms a hydrogen-bonding network with 
CD86 Glu-42 and Lys-49 that contributes to the stability of the interaction 
between CD86 and CTLA-4. 
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Figure 11 Ribbon Diagram of CD80 (B7-1) in Complex with CTLA-4 (from 
(185» Ribbon diagram shows two CD80 and two CTLA-4 molecules as observed in 
the asymmetric unit of the crystal structure. N-linked carbohydrates are shown. 
p-sheets involved in the receptor-ligand interaction are labeled. 
Figure 12 Ribbon Diagram of the CD86/CTLA-4 Binding Interface (from (186» 
Ribbon diagram of the binding interface between CTLA-4 (left) and CD86 IgV 
domain (right). The CDR3 loop of CTLA-4 that contains the MVPPPY motif is 
labeled. 
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1.5.7.1 The IgC domains in the crystals 
From the crystallographic studies, interesting differences in the IgC domains of 
CD80 and CD86 that may affect CTLA-4 binding were observed. Four extra 
amino acids in CD86 B-C loop (insertion 144--147 KKMS) and in CD86 C-D 
loop (insertion 150-153 LRTK) may change the overall conformation of the IgC 
domain in comparison to CD80. Because CTLA-4 does not bind directly to these 
residues, alterations in this area may affect CTLA-4 binding perhaps through 
altered dimerization capacity. Moreover, as shown in figure 13, numerous atomic 
contacts between the IgV and IgC domains of CD80 were uncovered, perhaps 
stabilizing the conformation of the variable domain (185, 227). These 
observations may explain earlier mutational studies that have highlighted the 
importance of IgC domains in CD80 and CD86 function. In addition, it was also 
proposed that glycosylation of Asn 173 located in CD80 IgC domain could have a 
profound effect on the stabilization of CD80 dimers (185). 
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Figure 13 BalI-stick Representation of the IgC and IgV Interface in CD80 
(from (227» The interdomain region of CD80 is shown with the membrane distal IgV 
at the top and the membrane proximal IgC domain at the bottom. The network of 
residues mediating interdomain contacts is shown in ball-and-stick representation. 
A hydrophobie core (formed by Val-8, Pro-74, Ala-106, Phe-134, and Leu-163) in 
addition to electrostatic contacts and hydrogen bonds (between Ser-75 and Glu-
162 and between Arg-73 and both Pro-159 and Glu-160) appear to stabilize the 
upright stature of the IgV domain of the molecule. 
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1.5.8 CD80 and CD86 dimers in CTLA-4 crystals 
The disulphide-linked CTLA-4 dimer can support binding of two independent B7 
molecules. The binding sites are distal to CTLA-4 dimer interface. Both CD80 
and CD86 were crystallized as dimers when complexed with CTLA-4. The CD80 
crystal lattice is dominated by a side-to-side molecular contact. This 'zipper 
arrangement' (shown in figure 14) is possible since CTLA-4 colligates CD80 
around an axis orthogonal to the membrane. Thus maintains the 140A 
intermembrane distance believed to be a critical feature of the IS (96). This type 
of binding is unique to CTLA-4/CD80 interactions. The biological relevance of 
the CTLA-4-B7 lattices was tested in a report from Darlington et al. (170) using 
CTLA-4 dimerization mutants. Interestingly, a monomeric CTLA-4 mutant still 
localized to the IS and inhibited T cell activation (170) in a CD80/CD86 
dependent manner. Counter receptor binding therefore appears to ultimately 
determine the formation ofCTLA-4 inhibitory lattices. 
Teell 
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Figure 14 CD80 and CTLA-4 Molecular Association in the Crystal Lattice 
(from (185» Shown are the 'zipper arrays' in which CTLA-4/CD80 complexes would 
be evenly spaced along membrane surfaces with a separation of 105A. In the 
perpendicular direction, across membranes, ligated receptors would span 140A. 
Geometrically, sugar chains (shown in ball-and-stick representation) attached at 
Asn 173 on CD80 (bottom) are close to the cell membrane perhaps stabilizing the 
orientation of the CD80 dimers. 
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ln the crystal lattice, CD80 was shown to fonn parallel 2-fold rotationally 
symmetric homodimers. Moreover CD80 has been shown to dimerize by other 
experimental approaches in many studies. First, when crystallized alone, 
deglycosylated CD80 is detected as a homodimer, as is fully glycosylated CD80 
in solution using analytical ultracentrifugation (227). The affinity of CD80 self-
association is consistent with CD80 existing at the cell surface in a dynamic 
equilibrium dominated by the dimer. In contrast, in the CTLA-4/CD86 complex, 
the two CD86 monomers are not related by perfect twofold rotational symmetry. 
Moreover, there is no data supporting CD86 dimerization. Analytical 
ultracentrifugation and gel filtration studies have showed that CD86 is monomeric 
in solution and the IgV domain of CD86 was shown to be monomeric in the 
crystalline state (256). Collins et al. suggested (184) that the potential 
glycosylation at the dimer interface (Asn-8) of CD86 would interfere with its 
dimerization. This hypothesis was invalidated since unglycosylated bacterially-
expressed CD86 did not fonn dimers. Moreover, CD80 crystal structure identified 
the dimer interface that involves Vll, V22, G45, M47, 158, D60, 161, T62, and 
L 70 contributed from the B, C", D, and E strands on the back sheet of the IgV 
domain (227). The majority of residues contributing to the dimer interfaces in 
CD80 and CD86 occupy the same positions in their respective primary sequences. 
When comparing these residues, the chemical properties of the dimer interfaces of 
CD80 and CD86 are very different. As shown in figure 15, the majority of the 
residues mediating CD80 dimerization are hydrophobic (shown in light grey) and 
the majority of the residues mediating CD86 dimerization are hydrophilic (shown 
in dark grey) (256). This dimer interface difference provides a mechanism for 
preventing the fonnation of CD80:CD86 heterodimers. Finally, unligated and 
ligated structures demonstrate that CD86 does not undergo any significant 
confonnational reorganization upon binding suggesting that CTLA-4 interaction 
could not have induced CD86 dimerization. Altogether, the deviation from 2-fold 
symmetry and the hydrophilic nature of the putative CD86 interface in addition to 
previous studies showing CD86 to be monomeric leads to believe that the 
observed CD86 dimers are the resuIt of crystal packing effect. Moreover, free and 
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complexed CD80 and CD86 proteins exhibit high structural similarity suggesting 
that receptor binding could not promo te nor enhance their dimerization. 
Figure 15 Surface Properties of CD80 and CD86 Dimer Interface (from (256» 
Comparison of the surface properties dimer interfaces of CD86 (left) and CD80 
(right). Hydrophilic residues are shown in dark grey while the hydrophobic 
residues are shown in light grey. It is obvious that hydrophilic residues dominate 
the CD86 dimer interface, whereas hydrophobic residues predominantly form that 
ofCD80. 
In a 2005 study, Bhatia et al. (257) used confocal microscopy-based fluorescence 
energy transfer (FRET) to demonstrate the different oligomeric states of CD80 
and CD86. CD86 was shown to exist as a monomeric population in fixed HELA 
cells while CD80 was present as a mixed population of monomers and dimers, 
with dimers predominating. The dimer interface proposed by prior 
crystallographic analysis was validated by a series of mutations in CD80 resulting 
in the expression of a predominantly monomeric species on the cell surface. 
Moreover, as suggested, no heterodimers between CD80 and CD86 could be 
detected at the cell surface. 
Altogether, CD28/CTLA-4/CD86/CD80 show great structural diversity that could 
account for the distinct functional properties of these interactions. 
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1.6 Cosignaling-based immunotherapeutics 
Cosignaling is of therapeutic interest because its manipulation might provide 
means to enhance or terminate immune responses. Preclinical studies exploring 
the role of members of the CD28 and B7 families have supported the targeting of 
these pathways for new therapeutic approaches. Numerous animal studies (229, 
258) and clinical trials (259) have shown that manipulating these interactions may 
hold promise for immunotherapy. 
1.6.1 Targeting CTLA-4 
Because of CTLA-4 negative regulation of T cell activation, reagents that block 
CTLA-4 could enhance T cell responses. CTLA-4Ig, a fusion protein containing 
the extracellular domain of CTLA-4 linked to an IgG1 Fc region, is the reagent 
that is the furthest in its therapeutic development and it appears likely that this 
reagent will be the first cosignaling therapeutic. CTLA-4Ig can block the 
interaction of CD28 with CD80 and CD86, and has been shown to suppress 
immune responses in multiple preclinical models of auto immune and 
inflammatory disease (260). CTLA-4Ig usage was first reported in patients with 
Psoriasis vulgaris were the reagent showed sorne efficacy (261). More recently, 
CTLA-4Ig has been tested in combination with methotrexate (MTX) in clinical 
trials of rheumatoid arthritis (259). Patients receiving CTLA-4Ig in combination 
with MTX showed better clinical improvement when compared with those 
receiving MTX alone. However, exacerbations of disease were also reported 
following CTLA-4Ig usage complicating predictions for therapeutic use. It was 
suggested that exacerbations might result from the loss of regulatory T cell 
function (90, 262). Using a different approach, a clinical trial in stage IV 
melanoma patients delivered anti-human CTLA-4 antibody along with tumor 
antigen epitope peptides. Tumor regression was observed although patient 
numbers was limited and several patients deve10ped manifestations of 
autoimmune responses that resolved after discontinuation of therapy. (263, 264) 
The anti-CTLA-4 antibody appeared to break tolerance to autoantigens. Further 
studies are needed to identify appropriate clinical strategies to maximize efficacy, 
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while minimizing auto immune si de effects. Definitely, despite sorne encouraging 
results, further studies will be needed to assess long-term efficacy and safety for 
CTLA-4Ig and anti human CTLA-4 antibody usage. 
1.6.2 CD28 superagonists 
Superagonistic CD28 antibodies generate a strong activating signal that bypasses 
the need for TCR signaling (265-267). CD28 superagonist administration in vivo 
has been shown to lead to preferential activation and expansion of naturally 
occurring CD4+CD25+CTLA-4+FoxP3+ Treg cells leading to the amelioration of 
auto immune diseases in preclinical models (265-267). Moreover, treatments over 
a broad dose range were never accompanied by side effects. Because of the 
success in preclinical studies, superagonistic CD28 antibodies were believed to be 
a promising novel treatment option. Very recently, the first phase 1 clinical trial of 
these antibodies was reported (268). Administration of TGN1412, a superagonist 
humanized anti-CD28 monoclonal antibody yielded unexpected results. The 
volunteers receiving this treatment suffered from a massive systemic 
inflammatory response syndrome. The exact mechanism of this devastating 
reaction awaits clearer description and will certainly help in the global 
understanding of cosignaling. 
1.6.3 Targeting CD80 and CD86 
Strategies to block CD80 and CD86 using antibodies have been promising in 
preclinical studies, including primate studies in transplantation (269) and in 
auto immune and inflammatory disease models (260). In vivo studies showing that 
CD80 and CD86 antibody blockade enhances and attenuates immune responses, 
respectively support the view that CD86 is largely activating and CD80 inhibitory 
(270-272). CD80 and CD86 antibodies are currently in early trials for the 
prevention of GVHD and psoriasis (273, 274). However, the therapeutic targeting 
of the costimulatory pathway by CD80 and CD86 antibodies may be complicated 
by expression of CD80 and CD86 on T cells. Downregulation of T cell responses 
through this expression may be a clinically desirable process (91). Moreover, the 
description of reverse signaling into CD80/CD86 expressing cells is a novel 
71 
aspect of CD80/CD86 function and may cause a variety of biological effects that 
have yet to be fully described (93, 94, 230). 
1.6.4 CD80 and CD86 as vaccine adjuvants 
Co-immunization of CD80 and CD86 has improved the efficacy of gene- and cell-
based vaccines in animal models and has shown promising results in pre-clinical 
tumor models (275-278). Recent use of B7 knockout mice in vaccine studies has 
confirmed that induction of immune responses to a DNA encoded antigen is 
critically dependent on CD86, but not CD80 (279, 280). Moreover, the timing of 
expression of CD80 versus CD86 appeared important in this model system (279, 
280). Because many tumors are poorly immunogenic due to the absence of B7 
proteins at their surface, alternative clinical approaches have explored the use of 
vaccination strategies with tumor cells expressing high levels of CD80 and CD86 
to enhance tumor immunity (281-284). These applications are at their early stages 
and will require robust clinical studies to assess their efficiency. 
Although substantial progress has been made in the cosignaling field, 
investigators continue to discover important biological functions for these 
molecules such as their function in peripheral tissues, in non-Iymphoid organs and 
lymphocyte homeostasis to name but a few. Understanding the physiological 
implications of aIl cosignaling molecules is necessary to comprehend T cell 
disregulation in auto immune and allergic diseases, for modulating transplant and 
tumor immunity and for the design of therapeutics targeting these molecules. The 
ultimate clinical utility of cosignaling therapeutics remains dependent on a more 
complete understanding of the complex biology of the CD28 and B7 families. 
1. 7 Project ration ale and thesis objectives 
Adaptive immune response initiation is entirely dependent on the interaction of a 
T cell and an APC in the context of the IS. During this interaction, an antigen 
specific and a costimulatory signal is delivered allowing full T cell activation. The 
cosignaling molecules CD86 and/or CD80 at the APC surface are absolutely 
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required in the generation of effective naïve T cell responses by binding to their T 
cell counter receptors, CD28 and CTLA-4. CD80 and CD86 are the founding 
members of the B7 cosignaling family and are type 1 membrane proteins that 
belong to the IgSF presenting an IgV and a IgC domain in their extracellular 
portion. Despite their shared receptors, different properties have been observed 
for both molecules including different expression kinetics, different binding 
properties, different signaling pathways and different functional properties. 
Although having been discovered more than a decade ago, many structural and 
functional characteristics of CD80 and CD86 are still elusive and await clear 
descriptions. A better understanding of the structure and function of CD80 and 
CD86 will help in understanding their different properties. Because of CD80 and 
CD86 crucial role in immune response initiation and termination, these and other 
cosignaling molecules are of high therapeutic interest. However, it is clear that a 
better understanding oftheir function is required before they are successfully used 
as immunotherapeutics. Moreover, with the description of several new members 
in the B7 cosignaling family, analysis of the domain properties of CD80 and 
CD86 could certainly act as a paradigm. 
An area of controversy in CD80 and CD86 function concems the contribution of 
the different domains in receptor binding. While crystallographic data show that 
only the IgV domain of both molecules is responsible for receptor interaction, 
substantial mutational analysis data have pointed towards a dual IgV/IgC 
implication. Another controversial issue is the molecular structure of these 
proteins at the cell surface. Although CD80 and CD86 have crystallized as 
homodimers, biophysical studies have suggested otherwise. These findings 
certainly need verification in a cellular context. Moreover, although the initiation, 
maintenance and function of the IS have been the subject of many experimental 
studies in T cells, the role of the APC and the APC surface molecules within this 
structure remains to be established. 
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The work presented in this thesis intends to establish the role of CD80 and CD86 
domains in their molecular structure and their role in naïve T cell activation. 
Specifically, the research objectives are to investigate the role of CD80 and CD86 
domains in respect to (a) their effect in the molecular structure of CD80 and 
CD86 (b) their contribution to receptor binding and (c) their overall impact on the 
cosignaling function ofthese molecules. 
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Chapter 2 
CD80 and CD86 IgC Domains Are Important for Molecular Structure, 
Receptor Binding and Cosignaling Function 
Work presented in this chapter investigates the role of the CD80 and CD86 
domains in their molecular structure, in their contribution to receptor binding and 
in their overall impact on the cosignaling function of these molecules. The 
experimental questions are answered through the use of wild type, deleted and 
chimeric CD80 and CD86 molecules. Methods used to answer the experimental 
questions are a peptide-specific cellular interaction system, a newly described 
cytometry-based fluorescence energy transfer method, non-denaturing gels and 
soluble receptors assays. 
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Abstract 
CD80 and CD86 are prototypical members of the B7 cosignaling molecules 
family and play pivotaI roles in naïve T cell activation. CD80 and CD86 present a 
membrane distal variable-like (lgV) domain, a membrane proximal constant-like 
(lgC) domain and an intracellular domain. CD80 and CD86 show several distinct 
features such as differential expression patterns, unique receptor affinities and 
distinctive oligomeric states. Crystallographic studies have clearly identified the 
IgV domain of both molecules as responsible for receptor interaction. However, 
many earlier studies suggested that both IgC and IgV domains are required for full 
cosignaling function. In this study, we characterized the role of CD80 and CD86 
domains in molecular structure using cytometry-based fluorescence energy 
transfer (FCET) and non-denaturing gels, in receptor binding properties using 
soluble receptors assays, and in cosignaling function in a peptide-specific cellular 
interaction model. We report the first detection of CD80 dimers and CD86 
monomers in live cells. Our FCET data combined to our biochemical results 
c1early show that the IgC domain inhibits multimer formation in both molecules. 
lndeed, CD80~C expressing cens showed greater dimer and multimer ratios when 
compared to CD80 wild type and CD86~C cens express CD86 as a mixed 
population of monomers and dimers in contrast to CD86 wild type that is only 
monomeric. The molecular structure ofboth molecules correlates with their CD28 
and CTLA-4 binding properties. Finally, both IgC and intracellular domains are 
shown to be required for full CD80 and CD86 cosignaling. These findings reveal 
the distinct but coupled roles of CD80 and CD86 domains in naïve T cell 
activation. 
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Introduction 
CD80 and CD86, also known as B7-1 and B7-2, are the prototypical members of 
the B7 cosignaling molecules family and are key players in the activation of naïve 
T cells. CD80 and CD86 are type 1 transmembrane proteins expressed mainly on 
antigen presenting cells (APC) and belong to the immunoglobulin superfamily 
(lgSF). They present two extracellular domains, with a membrane distal variable-
like domain (IgV), a membrane proximal Ig constant-like domain (lgC) and an 
intracellular domain. As typical Ig domains, both IgV and IgC consist of anti-
parallel beta sandwiches joined by a short linker region (224). These beta 
sandwiches are composed of an AGFCC'C" front sheet and a BED back sheet 
(185, 186). Despite sharing only 25% sequence identity, CD80 and CD86 bind to 
common receptors through the MYPPPY motif present in the CDR3 region of 
CD28 and CTLA-4 expressed on naïve and activated T cells respectively. Recent 
studies have however demonstrated CD28 to be the preferential receptor for CD86 
and CTLA-4 the preferential receptor for CD80 (155, 167). These cosignaling 
molecules are known to be present at the immunological synapse and their 
interaction leads to bi-directional signaling. Apart from different receptor 
affinities, CD80 and CD86 show several other distinct features such as differential 
expression patterns and unique oligomeric states. CD86 is expressed 
constitutively and is rapidly upregulated following T cell interaction while CD80 
is upregulated later in the immune response (229). Many mutational and structural 
studies have implicated residues of both the IgV and IgC regions of CD80 and 
CD86 for CD28 and CTLA-4 receptor interaction (247, 250, 253, 285). However, 
co-crystal structures of CD80 and the isolated IgV domain of CD86 complexed 
with CTLA-4 have shown that it is the IgV, and more specifically the front face of 
these molecules that contacts this receptor. No direct interaction between the IgC 
domain and CTLA-4 has been noted (185, 186). However, (185, 227) atomic 
contacts between the IgV and IgC domains of CD80 are thought to help stabilize 
the conformation of the IgV domain. Solution, crystallographic, biochemical 
structural and imaging studies have shown that CD80 predominantly exists as a 
dimer in a mixed dimer/monomer population at the cell surface and CD86 exists 
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solelyas a monomer (185, 186, 227, 256, 257). Sequence analysis of the dimer 
interface revealed that the majority of residues in CD80 are hydrophobie while 
those of CD86 dimer are hydrophilic (256). These differences not only support the 
difference in CD80 and CD86 multimeric state, but also provide a mechanism that 
prevents formation of CD80:CD86 heterodimers (256). In this study we aimed to 
better characterize the role of CD80 and CD86 domains in molecular structure, 
binding properties, and function using wild type, deletion and chimeric constructs. 
Molecular structure can be studied by measuring the fluorescence resonance 
energy transfer (FRET) between proteins coupled to CFP and YFP fluorescent 
proteins. FRET is the process by which an excited donor fluorophore transfers its 
non-radiative energy to an acceptor molecule when the emission spectrum of the 
donor overlays the absorption spectrum of the acceptor and when the distance 
between the donor and acceptor molecules is less than 100 angstroms (Â). When 
FRET occurs, there is an enhancement of the acceptor fluorescence and a 
quenching (attenuation) of the donor emission. FRET can be measured by 
different techniques such as spectrofluorimetry, confocal microscopy, and flow 
cytometry. Confocal microscopy FRET is an expensive and technically 
challenging technique that requires substantial acquisition and analysis time to 
achieve statistical significance. Moreover, it often relies on fixed cell samples. 
Flow cytometry based FRET (FCET) allows the quick analysis of a large number 
of live cell events making it a very good option to measure protein interactions. 
Using this method, we describe the first detection of CD80 homodimers and 
CD86 monomers in live cells and c1early identify an inhibitory role of IgC 
domains in multimer formation. This IgC-dependent molecular structure alteration 
impacts CD28 and CTLA-4 interaction. Finally, both IgC and IgT domains are 
shown to be required for full CD80 and CD86 cosignaling function. 
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Material and Methods 
Constructs generation 
cDNAs encoding for CD80 and CD86 wild type, deleted of their IgC domains 
(CD80~C, CD86~C) or deleted from their intracellular domain (CD80~T, 
CD86~T) as weIl as chimeric molecules VIC2T2 and V2CITI were previously 
described (254). These cDNAs were amplified with oligonuc1eotides containing a 
5' Xhol and a 3' SacIl restriction site for directional c10ning into the pECFP-NI 
and pEYFP-NI expreSSIOn vectors (Clontech). The sequence of the 
oligonuc1eotides were as follows: CD80Fwd 
CTCGAGGCCACCATGGGCCACACACGG; CD86Fwd 
CTCGAGGCCACCATGGGACTGAGT AAC; CD 8 ORev 
CCGCGGTACAGGGCGTAC; CD86Rev CCGCGGAAAACATGTATC; 
CD80~ TRev CCGCGGTCTTGGGGCAAAGCA; CD86~ TRev 
CCGCGGTTTCCATAGAATTAG. pECFP-Memb coding for a fusion protein 
consisting of the N-terminal 20 amino acids of neuromodulin that contains a 
signal that targets ECFP to cellular membranes was from Clontech and PEYFP-
Memb was c10ned by replacing the ECFP from pECFP-Memb by EYFP from the 
pEYFP vector. CD4 and CD4K3I8E in fusion with CFP and YFP were 
previously described (286). As a positive control for FRET, a CFP-YFP chimera 
(pECFPhYFP) plasmid was generated as follows. The pEYFP-NI vector was 
linearized with Nhel and the ends were blunted using T4 DNA polymerase. The 
DNA was then digested with Xbal to release the YFP insert, which was then 
inserted into the pBluescript II SK vector (Stratagene) that had been digested with 
EcoRV and Xbal, generating pSKYFP-Nl. A hinge (h) sequence, encoding three 
repeats of Gly-Gly-Gly-Gly-Ser, was generated by annealing the complementary 
oligonuc1eotides 5'- CCG GTG GGA GGA GGA GGC AGC GGC GGC GGA 
GGA AGC GGC GGA GGC GGA TC -3' and 5'- CAT GGA TCC GCC TCC 
GCC GCT TCC TCC GCC GCC GCT GCC TCC TCC TCC CA -3', and was 
ligated into AgelfNcol treated pSKYFP-NI, resulting in the plasmid pSKhYFP-
NI. This plasmid was digested with EcoRI, the ends were blunted by treatment 
with T4 DNA polymerase, and the hYFP insert was digested out with XbaI. This 
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fragment was inserted into the SmaIlXbal sites of pECFP-Cl yielding the fusion 
pECFPh YFP plasmid. 
Celllines and transfections 
The human epithelial kidney cellline 293T was obtained from ATCC. These cells 
were maintained in DMEM media supplemented with 10% FCS and 1 % 
penicillin-streptomycin. 293T cells were transfected using a calcium phosphate 
based method. Briefly, 1.2 million cells were seeded in 100mm plates, grown 
ovemight, and the media was refreshed 1 hour prior to transfections. DNA and 
calcium phosphate solution was added to HBS solution drop by drop and the 
mixture was added to the cells. Twenty-four hours following transfections, cells 
were washed and detached in PBS containing 3mM EDT A. The murine 
mastocytoma B2D cell line stably expressing HLA-DROlOl was previously 
described (287). These cells were transfected with 25ug DNA by electroporation 
at 260V and 950uF. Human CD28 positive Jurkat T cellline (A14 Jurkat T cells) 
derived from the CH7C17 Jurkat T cell line expressing a Va1.2Np3.l TCR 
specifie for HA306-318 peptide restricted to HLA-DROlOl was previously described 
(195). 
Antibodies and reagents 
CD80 antibodies used for flow cytometry analysis included PeCy5-conjugated 
anti-human CD80 clone L307.1 from BD Pharmingen, PE-conjugated anti-human 
CD80 clone 37711 from Rand D Systems and uncoupled anti-human CD80 
antibody clone BB 1 from ID Labs Canada. For immunoblots, anti human CD80 
clone 9091 was from Santa Cruz Biotechnology. CD86 antibodies used for flow 
cytometry analysis included PE-conjugated anti-human CD86 clone IT2.2 and 
clone FUNI from BD Pharmingen, unconjugated anti-human CD86 clone BU63 
from ID Labs Canada, and PE-conjugated anti-human CD86 clone HA52B7 from 
Beckman Coulter. For immunoblots, anti-human CD86 clone BU63 was used. 
CD28Fc and CTLA4Fc were purchased from R and D Systems. AH secondary 
antibodies were from Molecular Probes including. A polyclonal rabbit antibody 
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against CFP and YFP was from BD Phanningen. Peptide corresponding to 
residues 306-318 (PKYVKQNTLKLAT) of the influenza hemagglutinin protein 
(HA306-31S) was synthesized with >95% purity at the Sheldon Biotechnology 
Center (Montreal, Canada). p-actin antibody and CHAPS detergent were from 
Sigma. 
Flow cytometry Detection of FRET 
AlI flow cytometry was performed on a BD ™ Bioscience LSRII cytometer using a 
method adapted from (288). The Coherent Sapphire™ Solid state at 20m W power 
and the Coherent Vioflame™ Solid state 405-nm at 25m W power laser lines were 
used for YFP and CFP excitation respectively. The optical configuration is shown 
as supplementary data figure 1. Briefly, YFP signaIs were colIected using a 
524/10 bandpass filter in the primary laser pathway (laser 1). The CFP and FRET 
signaIs were colIected using 460120 and 585/42 bandpass filters, respectively, 
along with a 500 long-pass dichroic splitter filter inserted into Vioflame Solid 
state laser pathway (laser 2). Because FRET and YFP signaIs are detected on 
separate detectors in this configuration, the FRET process does not affect YFP 
signal. AlI F ACS data were analyzed using F ACS DIVA software (Becton 
Dickson, San Jose, CA). 
Western Blotting 
293T celIs were lysed on ice for 30 minutes in 1 % NP40, 5mM EDTA, 0.1 % SDS 
and protease inhibitors (Roche) containing buffer. For non-denaturing 
experiments, transfected celIs were lysed in 2% CHAPS buffer containing 10% 
glycerol and protease inhibitors (Roche). Lysates were cleared by centrifugation 
at 13000rpm for 10min. The amount of total protein in each sample was 
quantified with the Micro BeA assay (Pierce). Samples were then prepared with 
reducing (containing p-mercaptoethanol and SDS) or non-reducing loading buffer 
(buffer containing trypan blue and glycerol). The samples prepared with reducing 
loading buffer were boiled for 10 minutes and equal loads of protein were 
analyzed by SDS-PAGE and transferred onto polyvinylidene difluoride (PVDF) 
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membrane (Bio-Rad). The membranes were blocked for 1h at room temperature 
in PBS supplemented with 5% milk and probed with specifie antibodies overnight 
at 4°C under agitation. Blots were developed using horseradish peroxidase 
(HRP)-conjugated secondary antibodies (Sigma) and the ECL Chemiluminescent 
Detection System (Amersham Pharmacia). AlI quantification made use of the 
ImageQuant 5.1 program. 
Biochemical Fractionation 
This protocol was adapted from (289). 10x106 transfected 293T cell lines were 
pelleted, washed in PBS, resuspended in hypotonic solution (10 mM HEPES 
pH 6.9, 10 mM KCI, protease inhibitors) and incubated on ice for 20 minutes. 
Cells were disrupted by pipetting up and down 20 times. Nuclei were pelleted at 
3200 rpm for 10 minutes at 4°C. Supernatant from pelleted nuclei was centrifuged 
further at 35000 rpm for 30 minutes at 4°C. The supernatant (cytosolic fraction) 
was separated and the pellet (cytoskeletal plus membrane fractions) was 
resuspended in NTENT buffer (500 mM NaCI, 10 mM Tris-HCl pH 7.2, 1 mM 
EDT A, protease inhibitors and 1 % Triton X -100). This fraction was centrifuged at 
14000 rpm for 30 minutes at 4°C. The resulting pellet, resuspended again in 
NTENT buffer, comprised the cytoskeletal fraction, while the supernatant 
comprised the membrane fraction. 
FRET Efficiency and Molecular Distance Calculations 
As in (288), CFP quenching was measured by using two distinct FRET 
populations, a control negative FRET population in our case expressing pECFP-
Memb and pEYFP-Memb and the tested FRET population. The positions ofthese 
two populations were adjusted in a plot of YFP versus FRET in order to equalize 
their YFP intensities. In the advent that the tested population was FRET positive, 
CFP quenching was measured by subtracting the CFP MFI value of the FRET 
negative population from the CFP MFI value of the FRET positive population 
with both populations expressing equal YFP MF!. The FRET efficiency by F ACS 
(f/) was calculated using the following formula: 
83 
f/ = (I(CFP, FRET -) - I(CFP, FRET+)) / 1 (CFP, FRET-) 
where I[CFP,FRET-l and I[CFP,FRET+l are the CFP intensities in the negative and 
positive FRET populations, respectively, when both populations have equal YFP 
intensities. 
The relative molecular distance between two fluorophores (r) was calculated 
according to the formula: 
where Ro, the Forster radius, is the distance corresponding to 50% FRET 
efficiency and is about 50 A for a CFP-YFP pair (288). 
CD28Fc and CTLA4Fc Stainings 
Transfected 293T cells were incubated for 1 hour at 4°C with various 
concentrations of CD28Fc or CTLA4Fc. Cells were then washed and incubated 
for an additional 30 minutes with a secondary antibody specifie for human Fe 
coupled to Alexa fluor. After washing, cells were fixed in 2% paraformaldehyde 
and analyzed at the cytometer. To control for expression levels of the various 
proteins, data was analyzed by gating on equal MF! CFP populations. 
EC50 calculations 
ln brief, EC50 were determined as the amount of CD28Fc or CTLA4Fc resulting in 
50% positive cells as determined by flow cytometry staining. These calculations 
were made using a shareware MS excel worksheet ED50vlO. Briefly, the log 
concentrations of CD28Fc and CTLA4Fc were plotted on the x-axis and the 
corresponding % positive cells on the y-axis. The EC50 value was determined from 
the curve by reading out the x-axis value such that the y-axis value equals half of 
the peak value of the y axis. 
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ELISA 
B2D cells were electroporated with various YFP-fusion constructs and positive 
cells were cell sorted. The sorted cells were co-cultured ovemight with A14 Jurkat 
T cells at a 1:1 ratio at 37°C in round-bottom 96-well plates with various 
concentrations of HA peptide. Supematants were assayed for human IL-2 
according to manufacturer's instructions (BD Pharmingen). 
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Results 
Wild Type, IgC and Intracellular Domain Deleted CD80 and CD86 Proteins 
Are Recognized at the Cell Surface 
Wild type, IgC and IgT CD80 and CD86 constructs were cloned in frame with E-
CFP and E-YFP to generate fusion constructs expressing the fluorescent 
molecules at the C terminus. To test the expression and conformational integrity 
ofthese constructs, equal amounts ofwild type molecules (CD80 and CD86), IgC 
deleted molecules (CD80~C and CD86~C) and intracellular domain deleted 
molecules (CD80~T and CD86~T) (figure 1, panel A) were transfected in 293T 
cells. Their surface expression was tested using a number of different antibodies 
with unique binding specificities directed against the IgV domain of either CD80 
(clone L3074, clone 37711 and clone BB1) or CD86 (clone IT2.2, clone BU63, 
clone FUN1 and clone HA52B7). As shown in figure 1, panel B (CD80 stainings) 
and panel C (CD86 stainings) all tested cells were 100% positive for all antibodies 
tested. A difference was observed in the mean fluorescence intensity (MF!) of 
these stainings, especially between wild type and IgC deleted molecules. It was 
not clear if this MFI difference was due to poor antibody binding resulting from a 
conformational change introduced by the domain deletion or rather, if the 
constructs were expressed at different levels at the membrane. We therefore 
separated the cytoplasmic, membrane and cytoskeletal fraction of 293T 
transfected cells (figure 1, panel D). From these experiments, it is evident that the 
membrane expression levels of IgC deleted molecules were significantly lower 
than wild type and intracellular deleted molecules. We therefore hypothesize that 
the IgC deleted molecules are targeted for early degradation during synthesis or 
have a higher turnover at the membrane. These results explain, at least in part, the 
MFI difference of IgC deleted molecules when compared to their wild type 
counterparts. CD80 and CD86 intracellular domains associate to the cytoskeleton 
(225, 226, 290). As expected, intracellular domain deletion of CD80 and CD86 
molecules resulted in loss of their cytoskeletal association (figure 1, panel D). 
Importantly, CD80~C and CD86~C retained their cytoskeletal association even in 
the presence of the C-terminal fluorescent tag arguing again in favor of 
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conformational integrity conservation of these molecules. AlI isolated fractions 
were subjected to p38 probing and this molecule was either greatly enriched or 
only present in cytoplasmic fractions thereby confirming the specificity of our 
fractionation approach (data not shown). Altogether, despite IgC deleted proteins 
being expressed at lower levels, aIl generated clones were recognized by 
monoclonal antibodies of various specificities and the intraceIlular domains of 
both CD80 and CD86 retained their cytoskeletal association function indicating 
that the overaIl conformation of proteins under study was not dramaticaIly altered. 
FCET Detection of CD80 Dimers and CD86 Monomers in Live Cells 
CD80 and CD86 molecular structure was assessed by flow cytometric energy 
transfer (FCET) between CFP and YFP tagged molecules. We adapted the donor 
fluorophore quenching method from He et al. (288) that aIlows FRET efficiency 
quantification during CFP to YFP FRET. Because detection of donor CFP 
quenching becomes more reliable when molar ratio between CFP and YFP equals 
to 1, we documented comparable expression levels for each tagged protein by 
flow cytometry and biochemistry. As shown in figure 2 panel A, ceIls expressing 
equal amounts of any given CFP and YFP tagged constructs also presented highly 
similar MF!. To confirm comparable expression of these fusion proteins in 293T 
ceIls, immunoblots using an antibody that reacts with the common protein portion 
of aIl proteins related to GFP (XFP) were performed. As shown in panel B of 
figure 2, loading-corrected densities measured from the immunoblots showed that 
there is roughly the same amount of protein between CFP and YFP tagged 
constructs for aIl transfectants. Being ensured that the molar ratio was roughly 
equal to one, we proceeded to FCET experiments in 293T. CFP intensities were 
measured in an YFP versus CFP plot from YFP-equalized FRET -negative and 
tested condition populations and FRET efficiency by F ACS (f/) was calculated 
using the formula presented in the material and methods section. Of note, FCET 
efficiencies are always greater than the microscopy-based FRET efficiencies. The 
difference possibly results from the fact that FRET detection in living ceIls by 
flow cytometry is achieved within microseconds, which minimizes laser 
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photobleaching effects. As shown in panel C of figure 2 and summarized in panel 
D, FCET was always detected in cells expressing CD80, independently of IgC or 
intracellular domain deletion. Removal of CD80 intracellular domain resulted in a 
higher FRET efficiency (p::::;O.0409) while removal of its IgC domain resulted in 
somewhat of a decrease of FRET efficiency (p::::;O.0672). For CD86, no FCET was 
measured in cells expressing wild type molecules. Removal of CD86 intracellular 
domain did not affect its molecular structure but notably, the deletion of CD86 
IgC led to FCET detection. This is the first description of CD80 and CD86 
monomers and multimers in live cells and these data suggests that the CD86 IgC 
domain restrains CD86 from forming dimers. Because of the inverse correlation 
that exists between FRET efficiency and molecular distances, the derived relative 
biological distance between CFP and YFP moieties was calculated from the 
FRET efficiencies according to equation mentioned in the materials and methods 
section and is presented in figure 2, panel D. Not only does our FCET data concur 
with previously published microscopy-based FRET data that had shown that 
CD80 could be detected as a dimer but not CD86 (257), our positive controls all 
showed good FCET signaIs. This was the case for the fusion protein coding for 
both CFP and YFP separated by a 15 amino acid linker where the two 
fluorophores are so close that FRET is always detected. Other positive controls 
were CD4-lck, a cytoplasmic-membrane interacting pair (291), and Fas, a 
molecule known to trimerize (292). Using this distinct FRET approach, we 
obtained the same results previously obtained by showing FCET detection for the 
CD4 molecule and lost of this FCET signal with the dimerization impaired CD4 
K318E mutant (286, 293). Altogether, FCET experiments have led to the 
detection of a FRET singal for CD80 but not for CD86 thereby suggesting that 
CD80 exist as multimers and CD86 as monomers in live cells and deletion of 
CD86 IgC domain leads to the detection of a FRET signal therefore suggesting an 
inhibitory role for the IgC domain in multimer formation. 
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The Ige Domain Inhibits Multimer Formation in Both CD80 and CD86 
FCET measurements allow the detection of energy transfer between two 
fluorophores-tagged molecules; however, it does not allow the differentiation 
between dimerization and higher orders of interaction nor the detection of 
monomers. To further de scribe the role of the IgC and intracellular domains in 
CD80 and CD86 molecular structure, non-denaturing gels experiments were 
performed with 293T transfected cells. Cells were lysed in a 2% CHAPS buffer. 
The lysates were ran either in non-denaturing loading buffer composed of 
bromophenol blue and glycerol or boiled in SDS and p-mercaptoethanol 
containing loading buffer. One of three representative experiments is shown in 
figure 3. As shown in panel A, CD80 was mainly detected in monomeric form, 
followed by dimers, trimers and multimers. Following boiling (labelled as +), 
these multimeric forms disappeared. Highly similar results were obtained with 
CD80~T. Ofhigh interest, CD80~C expressing cells presented very low levels of 
CD80 monomers and high levels of multimeric forms composed of dimers, 
trimers, tetramers and multimers. Even after boiling, detection of CD80~C 
monomeric form was only slightly increased while the multimeric forms remained 
at the top of the gel although the dimeric, trimeric and tetrameric forms 
disappeared. This suggests that the multimers formed by CD80~C molecules 
somewhat resisted disruption by boiling. Results obtained for CD86 are shown in 
panel B, figure 3. Only monomers were observed for the wild type and CD86~T 
expressing cells. As anticipated from the FCET experiments, a dimeric form of 
CD86~C was detected. Following boiling in denaturing loading buffer, the 
dimeric form disappeared. The di mer and multimer ratio for each prote in was 
calculated by dividing the loading-corrected density of the relevant form to the 
total density as presented in panel C of figure 3. CD80 and CD80~ T showed 
similar dimer ratios but CD80~C showed a higher dimer ratio due to the higher 
amount of dimers detected. CD80 and CD80~ T showed a somewhat different 
multimer ratio but more strikingly, CD80~C showed a much higher multimer 
ratio, reflecting its propensity to form higher order complexes. These findings 
revealed that, as seen for CD86~C in FCET and non-denaturing gels experiments, 
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the IgC domain of CD80 also inhibits multimer formation. Altogether, these 
results complement the FCET data by showing that the IgC domain of both CD80 
and CD86 inhibit multimer formation. 
CD80 and CD86 IgC Domains Impact CD28 and CTLA-4 Binding 
To study the role of CD80 and CD86 domains in CD28 and CTLA-4 binding, we 
transfected 293T cens with CFP-tagged constructs and incubated the cens with 
various concentrations of soluble CD28 and CTLA-4 and then incubated with Fc 
specific secondary antibodies. Cytometry analysis was performed on cens 
presenting very comparable CFP MFI to control for expression levels. The results 
of one of three representative experiments are shown in figure 4. Results are 
shown either as % positive cens (figure 4 panel A) or as MFI values (figure 4 
panel B). Even when approaching close to 100% positive cells, CD80~C and 
CD86~C MFI remained low when compared to their wild type and intracenular 
domain deleted counterparts. From these binding curves, it was possible to 
determine the EC50 value for all proteins under study (figure 4, panel C). The 
EC50 value gives the soluble receptor concentration that binds 50% of the cells. 
EC50 values were lower for CTLA-4 than for CD28 since both CD80 and CD86 
bind CTLA-4 with higher affinity (184). The removal of the intracellular domain 
of both CD80 and CD86 appeared to confer a CD28 binding advantage since 
EC50 values were less than with the wild type molecules (O. 83ng/ml versus 
3.37ng/ml for CD86 and 0.08ng/ml versus 4.3ng/ml for CD80). Deletion ofCD80 
and CD86 IgC domain had a negative impact on both CD28 and CTLA-4 binding 
with CD86~C requiring 13.2 times more CD28Fc and 3.5 times more CTLA-4Fc 
and CD80~C requiring 183.3 times more CD28Fc and 73.7 times more CTLA-
4Fc when compared to wild type molecules. These results clearly indicate a role 
for both IgC and intracellular domains in ligand binding. 
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Both IgC and Intracellular Domains of CD80 and CD86 Are Required for 
Effective CD28-dependent IL-2 Production 
To study the functional relevance of CD80 and CD86 Ig domains in T cell 
activation, B2D cells, stably expressing HLA-DR0101, were electroporated with 
the various constructs. These cells were then cell sorted based on highly 
equivalent MFI and put in culture at al: 1 ratio with 0, 3 or 10ugimi of HA 
peptide and CD28 positive T cells expressing a HA-specifie TCR. One of three 
representative experiments is shown in figure 5. Cells expressing mYFP did not 
induce any response showing the cosignaling dependence of this system. Cells 
expressing CD80 and CD86 wild type molecules led to a dose-dependent T cell 
IL-2 secretion. Deletion of the intracellular do main of both CD80 and CD86 
almost completely abrogated IL-2 production. This result is in agreement with our 
previous findings and those of others (225, 226, 290) showing the critical role of 
CD80 and CD86 cytoskeletal association. Deletion of the IgC domain of both 
CD80 and CD86 also led to a defect in T cell activation as measured by IL-2 
secretion. At all HA peptide concentrations, the IL-2 response of CD80i1C and 
CD86i1C expressing cells was lower than their wild type counterparts. CD80i1C 
and CD86i1C expressing cells show differences in their multimer ratio that 
impacts their binding to CD28. These results show that the receptor binding 
impact seen in the soluble CD28 binding assays is correlated with T cell 
activation. Altogether, this data shows a functional role for aIl CD80 and CD86 
domains in co-stimulation ofT cell activation. 
The IgC domains Show Inhibitory Function in CD80/CD86 Chimeras 
FCET and biochemical results using IgC deleted construct showed that both 
CD80 and CD86 IgC domains inhibit multimer formation. In order to deepen our 
understanding of the Ige impact on molecular structure, we measured FCET 
using chimeric CD80/CD86 molecules as shown in figure 6. V80C86T86, 
expressing the IgV domain of CD80 and the IgC and intracellular domain of 
CD86 showed a drastic reduction in its FRET efficiency when compared to the 
wild type CD80 molecule. In contrast, when the IgV domain of CD86 is 
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expressed with the IgC and intracellular domain of CD80, CD86 remams a 
monomer. These results show that although the IgV domain present the dimer 
interface, the IgC domain impacts the overall molecular structure since CD86 IgC 
domain introduction in CD80 leads to the loss of dimer detection in live cells. 
92 
Discussion 
CD80 and CD86 are both type l membrane proteins members of the IgSF 
displaying a membrane distal IgV domain, a membrane proximal IgC domain and 
an intracellular domain. Crystal structures of CD80 and CD86 complexed to 
CTLA-4 c1early identified the crucial role of the IgV domain in mediating 
receptor binding (185, 186). AIso, both CD80 and CD86 crystallized as dimers in 
complex with CTLA-4. The dimer interface is contributed by the back sheet of the 
IgV domain ofboth CD80 and CD86 (227). Although the dimer interfaces occupy 
the same positions in CD80 and CD86 primary sequences, their chemical 
properties greatly differ. Indeed, CD80 dimer interface is hydrophobic while 
CD86 dimer interface is hydrophilic (256). Moreover, although CD80 was shown 
to form parallel2-fold rotationally symmetric homodimers, CD86 dimers deviated 
from ideal two-fold rotational symmetry. Moreover, free and complexed CD80 
and CD86 exhibit high structural similarity suggesting that receptor binding do es 
not promote or enhance dimerization. Because of these findings, it is believed that 
the observed CD86 dimers in the CD86: CTLA-4 crystals resulted from crystal 
packing. Importantly, Bhatia et al. (257) have shown by microscopy-based 
photobleaching FRET that CD80 predominantly exists as a dimer and CD86 as a 
monomer at the cell surface of fixed HELA cells. Moreover, even upon 
introducing a cysteine residue thought to favor dimer formation, CD86 gives a 
very low FRET efficiency suggesting that it may have a tendency to resist 
dimerization. Although no direct contact between the IgC domain of CD80 and 
CD86 and CTLA-4 were observed in the crystals, earlier mutational and structural 
studies have showed that amino acids within both the IgV and IgC domains of 
CD80 and CD86 can significantly affect receptor binding and the overall 
cosignaling function of these molecules (247, 250, 253, 285). These studies have 
shown that addition or deletion of certain amino acids in CD80 and CD86 Ig 
domains could significantly alter the function ofthese proteins and that neither the 
IgV domain nor the IgC domain can act independently to pro vide full cosignaling 
function. 
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In an attempt to better understand the role of CD80 and CD86 Ig domains in their 
functional properties and molecular structure, we generated deletion and chimeric 
constructs of CD80 and CD86 in frame with either the CFP or YFP protein. First, 
we established by antibody staining and biochemical fractionation the expression 
and functional integrity of these constructs. Then, using a donor-quenching flow-
cytometry based FRET method we showed that CD80 is detected as a dimer at the 
surface of live cells while CD86 is only detected as a monomer. These results are 
in agreement with those of Bhatia et al. that used a different FRET method (257). 
Moreover, we showed that CD86 is detected as dimers upon removal of the IgC 
domain suggesting an inhibitory role of the IgC domain of CD86 in dimer 
formation. We extended these findings by studying the molecular structure of 
these proteins by non-denaturing SDS-P AGE. This led to the observation that 
upon removal of the IgC domain of both CD80 and CD86, higher orders of 
multimerization was observed as seen as an increase of the dimer and multimer 
ratio. It is therefore clear from our observations that the IgC domain ofboth CD80 
and CD86 are important in regulating the molecular structure of these molecules 
by impacting their dimerization capacity. Crucially, the molecular state of CD80 
and CD86 greatly impacts their function as measured by receptor binding 
affinities and cosignaling function as determined by IL-2 secretion. 
In an earlier report, Bajorath et al. (224) identified CD80 and CD86 IgC 
sequences to resembled that of the p2-microglobulin. This suggested that like 
p2m, the CD80 and CD86 IgC region could be involved in protein-protein 
interactions. Because it is clear from the crystal that the IgC domains of CD80 and 
CD86 do not contact the CTLA-4 receptor, this plausible interaction might occur 
with the membrane distal IgV domain. Of note, numerous atomic contacts 
between the IgV and IgC domains of CD80 have been described and we believe 
that the interaction of the IgC with the IgV impacts the dimer interface present in 
the IgV domain. 
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Moreover, it was also proposed from the crystal structure of CD80/CTLA-4, that 
CD80 IgC glycosylation at Asn 173 might stabilize CD80 dimers by the 
interaction of sugars residues with the plasma membrane. Analysis of the amino 
acid sequence of CD86 and CD80 revealed interesting differences in the IgC 
domain of these molecules (257). Four extra amino acids either in the B-C loop 
(insertion 144--147 KKMS) or in the C-D loop (insertion 150-153 LRTK) in the 
CD86 molecule were observed. These insertions could lead to a conformation 
difference of the B-C or C-D loop of the CD86 molecule in comparison to CD80 
that might explain the molecular structure difference between the two molecules. 
Interestingly, we have shown that introduction of the IgC domain in CD86 led to 
an almost complete abrogation of CD80 dimer detection by FCET. This result 
agrees with the fact that CD80 and CD86 IgC domains are different and impact 
the dimerization capacity ofthe molecules. 
CD28 is a monovalent dimer and CTLA-4 is a bivalent dimer. Upon removal of 
the IgC domain of both CD80 and CD86, and therefore accumulation of higher 
order multimers, CD28 binding was greatly impacted as shown by the ca1culated 
EC50. CTLA-4 binding was also impacted by the presence of multimers. 
Although CTLA-4 prefers dimeric ligands such as CD80, CD86~C dimer binding 
to CTLA-4 was not favored. This might be explained by the observation of the 
CD86 dimer not being in appropriate conformation for receptor binding upon 
dimerization as observed in the crystal and its suggested tendency to resist 
dimerization. The CD28 binding data was correlated to functional read-out by 
measuring IL-2 secretion following peptide-specific interaction with CD28 
positive T cells. At 10uglml HA peptide, the IL-2 response was lower with the 
CD86~C expressing cells when compared with wild type. The same phenomenon 
was observed with CD80 and CD80~C. These results are in accord with those of 
others (254, 255) that studied these molecules in other in vitro and in vivo 
contexts. Vasu et al. also showed that a chimeric CD80 molecule expressing 
CD86 IgC domain was better at initiating responses than CD80 wild type. In vivo 
studies (254) have also shown that immunization with a cosignaling molecule 
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expressing CD86 IgC domain but the rest of CD80 led to a better anti RIV 
response. In view of our findings, this can be explained by the fact that the 
monomeric form is favored in this chimeric molecule and is therefore a better 
ligand for CD28. In contrast to our results, in the Agadjayan study (254), CD80dC 
was shown to be a better cosignaling molecule. We have shown that upon 
removal of its IgC domain, CD80 now forms higher order multimers and therefore 
is not a CD28 appropriate ligand. This conflicting data can certainly be explained 
by the complex interplay between CD28 and CTLA-4 in this in vivo model. 
CD80~C is not a better co-activator but rather a less potent co-inhibitor due to its 
affinity loss for CTLA-4 resulting in an overall increase in cosignaling response. 
In this c1ear from our data and that of others that the distinct molecular 
organization of CD80 and CD86 account for their overlapping yet distinct effects 
on T cell responses. Both CD86 and CD80 and their receptors, CD28 and CTLA-
4, are concentrated at the IS (150, 155, 294). The different oligomeric states of 
CD80 and CD86 indicate that these molecules form cosignaling complexes with 
distinct cell surface organizations, which may represent an important mechanism 
modulating their functional properties. Interestingly, it was recently demonstrated 
that B7 binding ultimately determines the formation of dimer-dependent CTLA-4 
lattices necessary for T cell inactivation (170). These results emphasize the crucial 
role of CD80 and CD86 molecular structure in their function. In this study, we 
have identified a role for the IgC domain of CD80 and CD86 proteins in dimer 
formation. IgC domains of both molecules regulate the molecular structure of 
CD80 and CD86 directly impacting on their ligand binding and cosignaling 
properties. 
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Conclusion 
Despite having been discovered more than a decade ago (211-213), the structural-
functional relationships of CD80 and CD86 Ig domains remained ill defined. Our 
CUITent findings described a role for CD80 and CD86 IgC domains in 
multimerization. Although the receptor interaction and the dimer interface aIl 
localized to the IgV portion of the molecule, the IgC impacts the dimer interface 
thereby directly influencing receptor binding properties. Because CD28 favors the 
binding of monomeric ligands and CTLA-4 that of dimeric ligands, the ratio of 
available CD80 and CD86 multimeric forms impacts the ensuing immune 
response. CD80 and CD86 are key players in naïve T cell activation. By better 
delineating the structural functional relationships between the domains that 
composed these molecules, we have better chances in regulating immune 
responses for therapeutic purposes. 
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Figure Legends 
Figure 1 Ali CD80 and CD86 Constructs Are Recognized at the Cell Surface 
by IgV Specifie Antibodies 
A) Schematic representation of the deletion constructs used in this study. CD80 
and CD86 are wild type molecules. CD80~C and CD86~C are deleted of their 
extracellular IgC domain. CD80~ T and CD86~ Tare deleted of their intracellular 
domain. B) CD80 antibody stainings of 293T cens expressing CD80, CD80~C or 
CD80~T. One of two representative experiments is shown. Bars represent MFI 
values obtained from the stainings while the % positive cens is shown as the line 
on top of the bars. C) CD86 antibody stainings of 293T cells expressing CD86, 
CD86~C or CD86~ T. One of two representative experiments is shown. Bars 
represent MFI values obtained from the stainings while the % positive cells is 
shown as the line on top of the bars. D) Sub-ceIlular fractionation of 293T cells 
expressing various CD80 and CD86 forms. C: cytoplasmic fraction, M: 
membrane fraction, Sk: cytoskeletal fraction. The loading-corrected membrane 
expression density for each prote in is shown. 
Figure 2 FCET Detection of CD80 Dimers and CD86 Monomers in Live Cells 
A) CFP and YFP MFI values for an constructs transfected in 293T cens. B) 
Biochemical analysis of the protein levels for aIl constructs. The loading-
corrected expression of each prote in is shown. One of two representative 
experiments shown. C) FCET results representative of five independent 
experiments. FRET efficiencies in % for each prote in under study. D) FRET 
efficiencies and calculated molecular distances between CFP and YFP tags of 
given proteins. 
Figure 3 The IgC Domain Inhibits Multimer Formation in CD80 and CD86 
Samples were ran on SDS-PAGE gels in non-denaturing or denaturing (+) 
conditions. A) CD80 results. Monomeric and multimeric forms are identified. 
CD80~C presents low levels of monomers and higher levels of multimers. B) 
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CD86 results. Monomeric and dimeric forms are noted. C) Calculated dimer and 
multimer ratio from loading-corrected expression densities. Results pooled from 
three independent experiments. 
Figure 4 CD80 and CD86 IgC Domain Deletion Impact CD28 and CTLA-4 
Binding 
293T cens were transfected with CFP relevant constructs. cens were incubated 
with various concentrations of soluble CD28 or soluble CTLA-4. A secondary 
reagent was used to detect soluble receptors and cells were analyzed by flow 
cytometry. Legend shown on the right. A) Results from soluble receptor binding 
shown as % positive cens. B) Results from soluble receptor binding shown as 
MF!. C) Calculated EC50 values, representing the concentrations of soluble CD28 
or CTLA-4 that resulted in 50% positive cens. 
Figure 5 Both IgC and IgT Domains of CD80 and CD86 Are Required for 
Effective CD28-dependent IL-2 Production 
B2D cells were electroporated and cell sorted based on YFP fluorescence. Sorted 
cens were put in ovemight culture with CD28 positive T cens in the absence or 
presence of 3uglml or 10ugiml HA peptide. IL-2 production was measured by 
ELISA. The obtained values are shown as IL-2 pglmllevels while the legend on 
the right indicate the HA peptide concentration. 1 of 3 representative experiments 
shown. 
Figure 6 IgC Domain Show Inhibitory Function in CD80/CD86 
Chimera 
FCET experiments using chimeric CD80/CD86 constructs. FRET efficiency is 
greatly reduced upon presentation of the IgV domain ofCD80 by CD86. 
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Legends for Data Not Shown 
Figure 1 Validation of the Fractionation Technique by p38 Probing 
p38 immunoblot on subcellular fractions obtained from 293T cells. As expected, 
p38 is greatly enriched in the cytoplasmic fractions. 
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Figure 1 Ali C080 and C086 Constructs Are Recognized at the Cell Surface by IgV-Specific Antibodies 
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Figure 2 FCET Detection of CDSO Dimers and CDS6 Monomers in Live Cells 
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Figure 3 The IgC Domains Inhibits Multimer Formation in CD80 and CD86 
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Figure 4 CD80 and CD86 IgC Domain Deletions Impact CD28 and CTLA4 Binding 
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Figure 5 Both IgC and IgT Oomains of C080 and C086 Are Requlred for Effective C028-0ependent IL-2 Production 
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Figure 6 IgC damain Shaw Inhibitary Functian in CD80/CD86 Chimeras 
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Supplementary Figure 1 LSR Il Configuration for FCET 
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Supplementary Figure 2 FCET Gating Strategy 
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Chapter 3 
CD86 Cytoskeletal Association is Necessary for Immunological Synapse 
Localization and Effective Co-Stimulation 
Work presented in chapter 3 investigates the role of CD86 intracellular domain in 
the cosignaling function of this molecule. The experimental questions are 
answered through the use of wild type, deleted or mutated CD86 constructs. 
Methods used to answer experimental questions are a peptide-specifie cellular 
interaction system, conjugate formation assay by cytometry, soluble receptor 
assays, biochemical fractionation and confocal microscopy imaging. 
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Abstract 
T cell activation requires both an antigen specific and a co-stimulatory signal 
delivered by antigen presenting cells (APC) in the context of the immunological 
synapse (lS). Reorganization of the cytoskeleton is required for the formation and 
maintenance of the IS. Our results show that CD86 is constitutive1y associated to 
the cytoskeleton in primary human APC as well as in a murine APC model. A 
highly conserved sequence present in all CD86 intracellular domains of higher 
mammals, the K4 motif, is critical for this association and CD86 localization at 
the IS. Importantly, APC expressing this mutated CD86 are severe1y impaired in 
their capacity to trigger complete T cell activation upon peptide presentation 
probably due to their lack of physical association with the cytoskeletal ERM 
proteins. Altogether, our data reveals the critical importance of cytoskeleton-
dependent CD86 polarization for effective co-stimulation. 
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Introduction 
Interactions between naïve T cells and APC in the context of the immunological 
synapse (lS) provide the two key signaIs for T cell activation. The tirst signal 
requires TCR engagement by a foreign antigen presented by MHC molecules 
while the second signal involves the engagement of CD28 by CD86. Co-
stimulation through B7 proteins such as CD86 (B7-2) and CD80 (B7-1) is 
essential for IS formation (153). CD80 is believed to be functionally linked to the 
cytoskeleton since removal of its intracellular domain impacts CD80 membrane 
redistribution following T ceIl interaction and inhibits full T ceIl activation (156, 
225, 226). We identitied a conserved region within human CD86 cytoplasmic 
domain at residues Lys265-268. This motif, detined herein as the K4 motif, is 
conserved in all higher mammalian CD86 sequences examined. This region is 
reminiscent of CD80 RRNE region, previously shown to be important for CD80 
mediated co stimulation, leading to our hypothesis that CD86 is associated to the 
APC cytoskeleton and that this association is of functional relevance for its co-
stimulatory function. We show here that CD86 is indeed associated to the APC 
cytoskeleton through its K4 motif and that CD86 physicaIly interacts with ERM 
proteins. Importantly, CD86 cytoskeletal association is critical for T cell 
activation. 
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Material and Methods 
Recombinant DNA Constructs 
Cloning of CD86wt and CD86i1 T in the eukaryotic expression vector Sra neo was 
previously described (254). CD86-K4 was generated by overlap PCR using the 
following primers: K4fwd 
GAAATGGGCGGCGGCGGCGCGGCCTCGCAACTCTTAT AAATG, K4rev 
CATTTATAAGAGTTGCGAGGCCGCGCCGCCGCCGCCCATTTCC, 
CD86fwd 
GGCTGACCCGGGTCTGAGCCACCATGGGACTGAGTAACATTCTC ~d 
CD86rev GTATCTTATCATGTCTGGATCC. CD86-K4 was cloned in the Sra 
neo vector as a BamHI and SmaI fragment. 
Antibodies and Reagents 
CD86 antibodies used in this study included clone IT2.2 (BD Pharmingen) for 
cytometry analysis and clone BU63 (ID labs, C~ada) for immunoblotting. ERM 
and NF-KB ~tibodies were from Cell Signaling Technologies. Secondary 
antibodies ~d Pro long Antifade mounting media were from Molecular Probes. 
HRP-coupled cholera toxin was from Sigma-Aldrich. Antibodies against hum~ 
MHC class I, CD83, TCR, CDl9 and CD14 were from BD Pharmingen. Influenza 
hemagglutinin peptide (HA306-318; PKYVKQNTLKLAT) was synthesized with 
>95% purity at the Sheldon Biotechnology Center (Montreal, Canada). 
Cell Lines and Transfections 
Murine B2D cells (287) were transfected with 30 Ilg DNA by electroporation at 
260V ~d 950llF ~d selected with G418 (0.8Ilg/ml). Aseptic cell sorting (MoFlo, 
Cytomation) was used to generate cellular clones of the tr~sfect~ts. CD28neg 
~d CD28pos Jurkat T cells express a Va1.2Np3.1 TCR specifie for HA306-318 
peptide restricted to HLA-DR0101 (195). The Daudi B cell line was obtained 
fromATCC. 
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Dendritic Cells Generation and Culture 
Human PBMCs obtained from healthy donors were depleted of CD3+ T cells by 
rosetteSep kit (StemCell) and CD14+ cells were isolated by autoMACS. 
Monocytes were plated at a density of 1x106 million cells per ml in RPMI1640 
medium supplemented with 1 % human serum (GemCell), 100U/ml penicillin, 
100ug/ml streptomycin, 10mM HEPES, 2mM L-glutamine, 1 % non-essential 
amino acids (GIBCO), 200U/ml IL-4 (Sigma) and lOOOU/ml GM-CSF 
(Cangene). Cells were supplied with 1.5ml of fresh medium containing 200U/ml 
IL-4 (Sigma) and 1000U/ml GM-CSF (Cangene) on day 2,4, and 6. mDes were 
obtained by harvesting non-adherent cells on day 7 and stimulating them with 
TNF-~, 1 T]g/ml (Biosource), IL-1p lOng/ml (Bio source), PGE2 1J..lg/ml (Sigma), 
and IL-6 1000U/ml (Biosource) for 48h. DC purity assessed by flow cytometry 
and was always higher than 95%. 
Biochemical Subcellular Fractionation 
The protocol is described elsewhere (289). Briefly, 10x106 dendritic cells or 
30x 1 06 B2D cell lines were resuspended in hypotonic solution (10 mM HEPES 
pH 6.9, 10 mM KCI, protease inhibitors) and incubated on ice for 20 minutes. 
Cells were disrupted by pipetting up and down 20 times. Nuclei were pelleted at 
3200 rpm for 10 minutes at 4°C. Supematant from pelleted nuclei was centrifuged 
further at 35000 rpm for 30 minutes at 4°C. The supematant (cytosolic fraction) 
was separated and the pellet (cytoskeletal plus membrane fractions) was 
resuspended in NTENT buffer (500 mM NaCI, 10 mM Tris-HCl pH 7.2, 1 mM 
EDT A, protease inhibitors and 1 % Triton X -100). This fraction was centrifuged at 
14000 rpm for 30 minutes at 4°C. The resulting pellet, resuspended again in 
NTENT buffer, comprised the cytoskeletal fraction, while the supematant 
comprised the membrane fraction. 
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Raft Isolation 
Lipid rafts isolation was perfonned using sucrose gradient ultracentrifugation of 
cell lysates as described elsewhere (295). Brifely, 108 cells were washed in ice-
co Id PBS and lysed in 0.5 ml ofcold buffer (1% TritonX-100, 20 mM of MES, 
and 150 mM ofNaCI, pH 6.5, containingprotease inhibitors (Roche). The lysates 
were then subjected to sucrose gradient fractionation using ultracentrifugation 
(100000 xg, 4°C, 17 h). Eleven to 12 fractions of 1 ml were collected. A total of 
10 ,Û of each fraction was subjected to dot-blot analysis using HRP-conjugated 
cholera toxin (Sigma-Aldrich) to detect GM1, a positive marker of rafts. 
Immunoblotting 
AlI electrophoreses were perfonned on 10% SDS-PAGE gels, transferred to 
PVDF membranes and blocked for 1h. Primary antibodies were incubated 
ovemight. After washes, secondary antibodies coupled to HRP were incubated for 
45 minutes. Blots were revealed using ECL (Amersham). 
Co-immunoprecipitations 
5 millions Daudi B cells were lyzed in a NP40 1 % buffer containing proteases 
inhibitors, 10% glycerol and 50mM NaCI for 30 minutes on ice. The lysates were 
cleared by centrifugation and pre-cleared with protein-G sepharose for 1h 
(Amersham). CD86 specific or isotype-matched antibody was then added to the 
lysate and incubated ovemight in a rotator at 4°C. Protein G beads were then 
added for 1h. Beads were washed four times in co Id lysis buffer and proteins were 
detached by boiling in Laemli buffer for 5 minutes. 
IL-2ELISA 
1xI05 T cells and Ix105 B2D cell lines were co-cultured ovemight at 37°C in 
round-bottom 96-well plates with HA peptide. Supematants were assayed for 
human IL-2 according to manufacturer's instructions (BD Pharmingen). 
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Conjugate Formation 
APC were pre-pulsed with lO~g/ml of HA306-318 peptide for 2 hours at 37°C. 
lxl06 T cells and lxl06 HA-Ioaded B2D celllines were co-cultured in a 37°C 
water bath and then fixed in 2% paraformaldehyde for 20 minutes. Cells were 
stained with anti-human MHC class I and anti-human CD86 for lh at 4°C. Cells 
were analyzed using a BD F ACS Scan flow cytometer (Becton Dickinson). 
Immunological Synapse Imaging 
Images of conjugates were acquired on a Leica Confocal microscope, using a 63X 
oil-immersion objective. An average of lO images per condition were taken for 
each experiment. Image analysis was performed with the Northem Eclipse 
software. A fluorescence ratio was obtained by dividing the Mean Fluorescence 
Intensity (MFI) at the interaction interface with the total cell MF!. A ratio of 1 
indicates that the protein is homogenously distributed at the cell surface while a 
ratio greater than 1 indicates a specific accumulation of the protein of interest 
(296). 
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Results and Discussion 
CD86 is Associated to the Cytoskeleton 
The cytoplasmic tail of CD86 encompasses a highly conserved K4 motif 
reminiscent of the RRNE sequence of CD80 previously shown to be important for 
CD80 co-signaling function (226). We verified CD80 subcellular localization by 
biochemical fractionation using the Daudi B cellline. This fractionation technique 
allows the separation of cytoplasmic (C), membrane (M) and cytoskeletal (Sk) 
subcellular fractions (289). CD80 immunoblotting of the obtained fractions 
revealed that CD80 could be detected in both the membrane and the cytoskeletal 
fraction, confirming biochemically that CD80 is associated to the APC 
cytoskeleton (data not shown). The same procedure was performed to assess 
CD86 subcellular localization in primary human dendritic cells (DCs) (n=2). 
CD86 was detected in both the membrane and cytoskeletal fractions of both 
immature and mature human DCs (figure 1, panel B) c1early showing that CD86 
is associated to the cytoskeleton of primary professional APC. 
Constructs encoding either human CD86 wild type (CD86wt), human CD86 
truncated ofits intracellular domain (CD86~T) or human CD86 in which the four 
lysine residues of the K4 motif are mutated to alanines (CD86-K4) (figure 1, 
panel A) were used to generate stable cell lines in the murine mastocytoma B2D 
cellline (287). Following fractionation of these celllines, CD86 immunoblotting 
showed that the CD86 molecule was detected in the cytoskeletal fraction of 
CD86wt cells but not in CD86-K4 cells (figure 1, panel B). As expected, CD86 
from CD86~T cells was only detected in the membrane fraction. As a control, all 
fractions were subjected to NF-KB probing and this molecule was greatly enriched 
in cytoplasmic fractions thereby confirming the specificity of our fractionation 
approach (data not shown). These results c1early indicate that CD86 is associated 
to the cytoskeleton and that this association requires CD86 intracellular domain 
and most specifically the K4 motif. 
119 
Lipid rafts are membrane microdomains that are not readily solubilized in non-
ionic detergents (297). Because the non-ionic detergent Triton X-lOO was used in 
the subcellular fractionation protocol, raft isolation was undertaken to confirm 
that it was indeed cytoskeletal association rather than raft residence that conferred 
detergent resistance to CD86 molecules. Cholera toxin probing of dot blots 
showed that rafts were enriched in fractions 4 to 6 by (figure 1, panel C). CD86wt 
as well as its deleted and mutated forms were also found in comparable amounts 
in raft fractions obtained from the B2D cell lines (n=3) (figure 1, panel C). 
Therefore, the absence of the mutated (CD86-K4) and the truncated (CD86~T) 
forms of CD86 in the cytoskeletal fractions can only be explained by their lack of 
cytoskeletal association rather than lack of raft residence. 
CD86 Cytoskeleton Association is Important for IS Localization but Does not 
Affect Conjugate Formation 
Cytoskeletal association of cell surface proteins, such as CD80, has been shown to 
be crucial for their function in the IS (96, 156). We investigated the functional 
importance of CD86 cytoskeletal association on an early event of T cell 
activation, namely cell conjugation (n=3). CD28 positive or negative (CD28pos or 
CD28neg) Jurkat T celllines expressing a HA specific TCR were co-cultured for 
o to 45 minutes with B2D APC presenting this peptide. Cells were then fixed and 
stained with PE-Cy5-conjugated anti-human MHC class 1 (T cell specific) and 
anti-human PE-conjugated CD86 (B2D specific). T cell-APC conjugates were 
assessed by measuring the number of PEIPE-Cy5 double positive events by flow 
cytometry (figure 2 and data not shown). A background level of conjugation, 
consistently below 3%, was observed when CD28neg Jurkat T cells were used. 
For CD28pos Jurkat T cells, kinetic analyses showed that a maximum frequency 
of conjugates (26.6%) was obtained at 45 minutes, representing a 12.5-fold 
difference as compared to CD28neg Jurkat T cells. No difference in the efficiency 
of conjugate formation was observed between CD86wt and CD86-K4 cells. These 
results confirm the initial adhesion role mediated by CD86/CD28 interactions in 
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the earliest events of T cell-APC contacts (298). However, CD86 association to 
the cytoskeleton is not required at this early stage. 
To demonstrate the localization of CD86 at the IS, HA-pulsed primary mature 
DCs (figure 3, panel A) derived from a HLA-DR0101+ donor were co-cultured 
with CD28pos Jurkat T cells. The conjugates were then analyzed by confocal 
microscopy. An average of ten images per tested condition were taken in any 
given experiment. In mDCs, CD86 was reoriented towards the interaction 
interface with a fluorescence ratio of 1.85±0.33 (n=2) (figure 3, panel A and C) 
c1early demonstrating that CD86 is localized at the IS in primary professional 
APc. In B2D cell lines, CD86 was also strongly reoriented at the IS after a 30 
minute interaction between CD86wt and CD28pos Jurkat T cells with a 
fluorescence ratio of 2.58±0.38 (n=3) (figure 2, panel B and C). Reorientation in 
CD86-K4 cells was much less significant (p < 0.0001) with a fluorescence ratio of 
1.29±0.21 (n=3). These results c1early indicate that CD86 polarization to the IS is 
dependent on its interaction with the cytoskeleton through the K4 motif. Our 
results indicate that CD86 is actively recruited and/or retained at the IS in a 
cytoskeleton-dependent fashion. Mutation in the K4 motif prevents CD86 
interaction with the cytoskeleton (figure 1, panel A) and its accumulation at the IS 
following T cell interaction. Our findings are in agreement with previous studies 
showing the importance of the APC cytoskeleton in the formation of peptide-
dependent IS (34, 35, 299). 
CD86 Cytoskeletal Association is Critical for T cell Costimulation and IL-2 
Production 
To assess the physiological relevance of CD86 association to the cytoskeleton in 
late events of T cell activation, IL-2 secretion of CD28pos Jurkat T cells in 
response to antigen specific TCR triggering was measured by ELISA following an 
ovemight co-culture with APC expressing CD86wt or CD86-K4 (n=5). The 
system used herein is highly dependent on costimulation since absence of CD86 
expression resulted in the lack of IL-2 secretion even in the presence of optimal 
121 
concentrations of HA peptide (figure 4). Two independently derived CD86-K4 
clones expressing similar leve1s of CD86 when compared to CD86wt cells (data 
not shown) induced drastically lower IL-2 levels (3.6 to 13.1 fold lower) at all 
tested peptide concentrations. CD86 association to the cytoskeleton is thus of 
functional relevance for costimulation since IL-2 production by T cells is almost 
completely abrogated following stimulation by APC expressing CD86-K4. 
Impairment of T cell activation in this system could only result from the lack of 
cytoskeletal association of CD86 rather than inefficient ligand binding, since all 
B2D celllines bound soluble CD28 with comparable affinity (data not shown). 
Further evidence for the importance of CD86 cytoskeletal association is provided 
through the use of Latrunculin B, a cytoskeleton inhibitor. Latrunculin B treated 
CD86wt cells showed a completely impaired co-stimulatory activity to the same 
extent of T cell treatment with the same inhibitor as measured by IL-2 secretion 
(data not shown). 
CD28 has been proposed to be initially recruited to the synapse by TCR induced 
cytoskeletal remodeling, independently of CD86 binding; it is then stabilized 
through its interaction with CD86 on APC (155). CD86, located at the IS, is thus 
able to provide the necessary signal for proper co-stimulation of T cell activity. 
Our results and those of others (156, 225, 226) clearly indicate that the interaction 
of CD80 and CD86 with the cytoskeleton constitutes a general mechanism for the 
costimulatory function of these molecules by regulating their subcellular 
localization. 
CD86 Physically Associates with ERM Proteins 
CD86 K4 motif and CD80 RRNE motif are both positively charged amino acids 
c1usters. These types of sequences are often present at the juxtamembrane region 
of integral proteins. However, sorne cell surface molecules such as CD43, CD44, 
L-selectin, ICAM-2 and ICAM-3 are linked to the cytoskeleton through these 
aforementioned sequences by interacting with a family of membrane-cytoskeleton 
linkers, the ezrin/moesin/radixin (ERM) proteins (127). ERM proteins link 
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transmembrane receptors to the cortical actin cytoskeleton. We thus hypothesized 
that the K4 region of CD86 was an ERM binding region. In preliminary 
experiments, we attempted to co-immunoprecipitate CD86 and ERM proteins in 
the B2D cell lines. The results were unconvincing most probably due to low 
levels ofCD86 and/or ERM proteins in these celllines. We therefore chose to use 
the Daudi B cell line that expresses high levels of CD86 and more than twice the 
levels of constitutive ERM proteins (data not shown) when compared to B2D 
cells. CD86 immunoprecipitation in the Daudi B cellline allowed us to detect the 
physical interaction between CD86 and ERM proteins as shown in figure 5 (n=3). 
To our knowledge, this is the first description of a binding partner for CD86. 
The Two Signal Model in APC 
A question remaining from both earlier studies and the CUITent study is how are 
B7 proteins redistributed at the cell surface. We suggest a reciprocal two-signal 
model in APC that could involve a first signal triggered either through CD86 or 
MHC molecules (53, 300) inducing inactive cytoplasmic ERM proteins to adopt 
'open' active conformations. Signaling within APC would require initial 
conjugate formation through cytoskeletal relaxation (121) and CD28-CD86 
dependent adhesion. The second signal would involve recruitment or retention of 
CD86 to the IS by phosphorylated ERM proteins, allowing sustained T cell co-
stimulation. It is only in the context of a mature IS that CD86 could act as a potent 
co-stimulator and induce full T cell activation (294). This reciprocal two-signal 
model highlights the bi-directional nature of signaling in the IS (230) that leads to 
cytoskeletal reaITangements thereby creating an optimal environment for CD28-
B7 interaction and function. Altogether we provide evidence for the cytoskeletal 
regulation of CD86 cosignaling molecule function in APC. 
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Figure Legends 
Figure 1 CD86 Sub-cellular Distribution in Antigen Presenting Cells 
CD86 sub-cellular localization was assessed by fractionation in immature and 
mature primary dendritic cells (n=2) and in the B2D cell lines (n=3). A) 
Intracellular sequence of CD86 constructs used in this study B) Cytosolic (C), 
membrane (M) and cytoskeletal (Sk) fractions were isolated. CD86 
immunoblotting reveals that CD86 is associated to the cytoskeleton in immature 
and mature dendritic cells and in the CD86wt cellline. CD86 is not associated to 
the cytoskeleton in the CD86~ T and CD86-K4 celllines. C) CD86 from all B2D 
cell lines was present in rafts enriched in fractions 4 to 6 as shown by cholera 
toxin and CD86 dot blot analyses. 
Figure 2 CD86 Association to the Cytoskeleton Does not Affect Conjugate 
Formation 
Average results of 3 independent conjugate formation experiments. HA peptide 
pre-pulsed B2D celllines were co-cultured with CD28pos and CD28negJurkat T 
cells for 0 to 45 minutes and then stained with PE-conjugated anti-human CD86 
and PE-Cy5-conjugated anti-human MHC Class 1. Double positive (PE+ IPE-
Cy5+) events represent conjugates and is shown here as % conjugates. 
Figure 3 CD86 Localization to the IS Requires the K4 Motif 
Representative images of two (A) and three (B) independent experiments. An 
average of 10 images were taken per condition in each experiment. A) Human 
mature dendritic cells derived from a HLA-DR0101+ donor were pre-pulsed with 
HA peptide and co-cultured with CD28pos Jurkat T cells for 15 minutes at 37°C. 
Cells were then spun onto a slide, fixed and stained for CD86 (shown in green). 
AlI images were acquired on a Leica Confocal microscope using a 63X oil-
immersion objective. Confocal microscopy analysis reveals that CD86 relocates 
to the T cell:mDC interface after 15 minutes. B) CD86wt cells also present 
relocalisation of CD86 at the interface after 30 minutes of interaction with 
CD28pos Jurkat T cells whereas CD86-K4 cells do not show such relocalisation. 
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C) The calculated fluorescence ratio was obtained by dividing the MFI at the 
interaction interface with the MFI of the entire cell. 
Figure 4 CD86 Co-stimulatory Activity is Dependent on its K4 Motif 
CD86wt and two different CD86-K4 cellular clones expressing comparable levels 
of CD86 were co-cultured ovemight with CD28pos Jurkat T cells at al: 1 ratio 
with various HA peptide concentrations. IL-2 production was measured by ELISA 
in five independent experiments. 
Figure 5 CD86 and ERM Proteins Physically Interact 
CD86 was immunoprecipitated from Daudi B cell lysates (n=3). CD86 co-
immunoprecipitated a doublet representative of the 78Kda forms of radixin and 
moesin and the 80Kda ezrin protein. Ig = Isotype control, 
immunoprecipi tation. 
126 
IP = 
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Figure 2 CD86 Association to the Cytoskeleton Does Not Affect Conjugate Formation 
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Figure 3 COS6 Localization to the 15 requires the K4 Motif 
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Figure 4 CD86 Co-stimulatory Activity is Dependent on its K4 Motif 
300 
250 
E 200 
--Cl 
0.. 150 C\I 
1 
-l 
- 100 
50 
0 .. ~_L 
o ~1 ~3 3 
HA peptide ug/ul 
• COB6 Il C086-K4 (1) 0 C086-K4 (2) 0 B20 
130 
Figure 5 CD86 and ERM Proteins Physically Associate 
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Legends for Data Not Shown 
Figure 6 CD80 Sub-Cellular Distribution in Daudi B Cells 
CD80 sub-cellular localization was assessed by sub-cellular fractionation in the 
Daudi B cell line. Cytosolic (C), membrane (M) and cytoskeletal (Sk) fractions 
were isolated. CD80 immunoblotting reveals that CD80 is associated to the 
cytoskeleton of these cells. 
Figure 7 NF-kB is Greatly Enriched in the Cytoplasmic Fractions 
NF-kB immunoblots on subcellular fractions obtained from DCs or the B2D cell 
lines. As expected, NF-kB is either only present or greatly enriched in the 
cytoplasmic fractions. 
Figure 8 CD86wt and CD86-K4 Clones Express Comparable CD86 Protein 
Levels 
Flow cytometer histograms showing CD86 staining of CD86wt cells and two 
independently derived CD86-K4 clones. MFI values of these different cellular 
clones show comparable CD86 expression. These cells were used in the co-
culture IL-2 production experiments. 
Figure 9 Conjugate Formation Density Plots 
HA peptide pre-pulsed B2D cell lines were co-cultured with CD28pos and 
CD28negJurkat T cells for 0 to 45 minutes and then stained with PE-conjugated 
anti-human CD86 and PE-Cy5-conjugated anti-human MHC Class 1. Double 
positive (PE+ IPE-Cy5+) events represent conjugates. 
Figure 10 B2D APC Cell Lines Bind CD28 in a Similar Fashion 
B2D cell lines were incubated with soluble CD28 at the various concentrations 
indicated. After washing, cells were incubated with a secondary antibody coupled 
to Alexa 488. After washing, cells were analyzed on BD LSR II flow cytometer. 
Results indicate that all celllines bind CD28 with a comparable avidity (n=3). 
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Figure Il LatB Treatment Negatively Impacts CD86 Costimulation 
CD86wt or CD28pos Jurkat T cells were pre-treated with Latrunculin B for 30 
minutes at 37°C. Concentrations of Latrunculin B used are shown in parentheses 
following the treated cell type. After extensive washing, cells were co-cultured 
ovemight with untreated APC or T cells and various concentrations of RA peptide 
as indicated. Following the ovemight co-culture, viability of cells was monitored 
by flow cytometry using FSC/SSC parameters and IL-2 production was measured 
by ELISA. One of three representative experiments is shown. 
Figure 12 Surface Expression of CD86 is Not Altered by Latrunculin B 
Treatment 
CD86wt cells were treated with Latrunculin B for 30 minutes and then washed 
and put in culture for 16 hours. CD86 expression was monitored by flow 
cytometry before treatment (red histogram) and after the ovemight culture (blue 
histogram). CD86 surface expression albeit lower following treatment (MFI X 
versus Y) was not considerably altered following latrunculin B treatment. 
Figure 13 ERM Proteins Expression Levels of Daudi B Cell and B2D Cell 
Line 
Total ERM protein levels were measured by intracellular staining in B2D and 
Daudi B cells. 
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Chapter 4 
General Discussion 
136 
4.1 Molecular structure of CD80 and CD86 
4.1.1. Only wild type CD80 can form homodimers 
The crystal structure of CD80 and CD86 complexed with CTLA-4 were both 
reported in 2001 (185, 186). The crystals highlighted the crucial importance of the 
IgV domain of CD80 and CD86 in the interaction with CTLA-4. However, earlier 
evidence from mutagenesis and biophysical studies suggested that both IgV and 
IgC domains were implicated in CD80 and CD86 receptor binding. When 
complexed with CTLA-4, both CD80 and CD86 crystallized as homodimers. In 
contrast to the CD80 dimer, the CD86 dimers deviate from 2-fold symmetry and 
presents a hydrophilic rather than hydrophobie dimer interface. These 
observations, in addition to previous studies that showed CD86 to be monomeric, 
lead to believe that the reported CD86 dimers resulted from crystal packing. 
Therefore, the exact molecular structure of CD80 and CD86 remained to be 
confirmed. Moreover, the role of CD80 and CD86 functional domains in 
molecular arrangement needed to be established. 
In 2005, Bhatia et al. showed that CD80 existed as a mixed monomeric-dimeric 
population and CD86 as a monomer at the surface of fixed cells using 
microscopy-based FRET (257). The results presented in chapter 2 confirm and 
extend these findings in live cells. Cytometry-based FRET experiments show that 
CD80 is detected as a homodimer and CD86 as a monomer at the surface of live 
cells (figure 2, chapter 2). Interestingly, upon deletion of CD86 IgC domain, 
CD86 is detected as homodimers in live cells. Non-denaturing polyacrylamide gel 
electrophoresis (PAGE) experiments (chapter 2, figure 3) corroborate these 
findings and aiso reveals that CD80 IgC domain deletion leads to higher orders of 
CD80. Clearly, the IgC domain affects the multimeric structure ofboth CD80 and 
CD86. Additional FCET experiments confirmed the inhibitory effect of the IgC 
domain as shown by the loss of CD80 homodimer formation when the IgC 
domain of CD86 replaced the IgC domain of CD80 while keeping CD80 IgV 
domain (figure 6, chapter 2). A summary of the obtained results regarding the 
molecular structure of CD80 and CD86 is shown in figure 1. 
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A B 
CD80 Molecular Structure CD86 Molecular Structure 
C080 C08MT C080ilC C086 C086il T COSMC 
Figure 1 Molecular structure of CD80 and CD86 
The molecular structure of CD80 (panel A) and CD86 (panel B) as observed from 
FCET and biochemical experiments using wild type and deletion forms of CD80 
and CD86. CD80 wild type molecules exist as a mixed monomeric and dimeric 
population. Upon removal of CD80 IgC domain, higher orders of multimers are 
observed. CD86 exists as a monomer. Upon deletion of CD86 Ige domain, sorne 
homodimers are detected. Removal of intracellular domains in both CD80 and 
CD86 do es not greatly impact their molecular structure. 
4.1.2 The inhibitory function of CD80 and CD86 Ige domain 
CD86 presents two insertions of four amino acids within its IgC domain when 
compared to CD80. This divergence might explain the difference between CD80 
and CD86 molecular structure. Clearly, CD86 IgC domain differs from that of 
CD80 since V80C86T86 molecules did not homodimerize even if CD80's dimer 
interface is favourable for such formation. Conversely, CD80 IgC domain coupled 
to CD86 IgV domain in the V86C80T80 molecule did not allow homodimers 
formation. This c1early shows the dual requirement for a dimer interface with 
appropriate properties and the IgC domain presentation of the dimer interface for 
multimer formation. In the crystals, numerous atomic contacts between the IgV 
and IgC domains of CD80 were uncovered; these interactions might stabilize the 
conformation of the IgV domain (185, 227). The IgC domain could support the 
IgV mediated CTLA-4/CD28 binding by, for example, shielding the hydrophobie 
receptor binding domain. Glycosylation of the IgC domain might have a profound 
effect on the stabilization of CD80 dimers perhaps through the interaction of the 
sugar moieties with the membrane (185). 
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4.1.3 CD80 and CD86 molecular structure impacts receptor binding 
and cosignaling function 
Collins et al. (184) published pioneer data in 2002 that showed that CD86 is the 
preferentialligand of CD28 and CD80 the preferentialligand of CTLA-4. That 
same study showed that CTLA-4 is a bivalent homodimer while CD28 is a 
monovalent homodimer. This valency difference between CD28 and CTLA-4 was 
finally explained with the recent crystallization of CD28 in complex with an 
antibody Fab fragment (167). Although both CD28 monomers are available for 
binding, simultaneous docking of two B7 monomers is prevented by the physical 
clash of their IgC domains. Interestingly, Dennehy et al. showed that CD28 
monovalency is essential for the cosignaling phenomenon since ligation of an 
engineered bivalent CD28 induced responses in the absence of TCR engagement 
(246). 
Results presented in figure 4 of chapter 2 show that a change in the molecular 
structure of CD80 and CD86 directly impacts their receptor binding properties. 
Deletion of the IgC domains leads to higher order of CD80 and CD86 
multimerization, greatly affecting binding to monovalent CD28 as seen with the 
increased EC50 values. Binding defects were also seen when using soluble 
CTLA-4. Although CTLA-4 is bivalent and can form higher order arrays with 
CD80, multimeric CD80~C was not a better binder to CTLA-4. Assumingly, 
multimeric CD80 could not allow appropriate CTLA-4 binding perhaps through 
structural and physical constraints. Moreover, although present at the surface in a 
mixed monomeric-dimeric population, CD86~C binding to CTLA-4 was not 
favored. This could be explained by the fact that as observed in the crystal lattice, 
CD86 does not form symmetrical dimers leading to defective CTLA-4 binding. 
Altogether, these results clearly highlight the critical importance of molecular 
structure in the interactions of the B7/CD28 system. 
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In this thesis, CD80 and CD86 cosignaling function was studied in a peptide-
specific cellular interaction model. As an APC, the murine B2D cell line that 
stably expresses HLA-DROIOI was transfected with the CD80 or CD86 construct 
of interest. The responding T cell line was either a CD28 negative or CD28 
positive T cell expressing a Va1.2N~3.1 TCR restricted to HLA-DROI0l and 
specific for the HA306-318 peptide. Upon HA peptide presentation, responding T 
cells secreted IL-2 in a dose-dependent and cosignaling-dependent manner. The 
impact of the altered CD28 binding properties of CD80 and CD86 IgC deleted 
molecules was corroborated using this cellular interaction system. IgC deletion in 
both CD80 and CD86 lead to reduced IL-2 secretion as expected from their 
CD28-binding defect (figure 5, chapter 2). These results are in accord with results 
from Agadjanyan et al. (254) and Vasu et al. (255) who showed in 2003 that the 
chimeric molecule expressing the IgV domain of CD80 and the remaining portion 
of CD86 (V80C86T86) enhanced T cell activation in vivo and in vitro. In view of 
our results, this observation can be explained by CD80 IgV being mostly present 
as a monomer at the cell surface and therefore being more suited for CD28 
binding and cosignaling. Altogether, our findings and those of others show that 
both the IgV and IgC domains are crucial for CD80 and CD86 function. A 
summary of the interaction properties and ensuing responses is presented in 
figure 2. 
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Figure 2 Molecular interactions of wild type and deleted forms of CD80/CD86 
A) Physiological Impact of CD28 Interactions. For discussion purposes, both 
CD80 and CD86 are presented but CD28:CD86 interactions are more likely than 
CD28:CD80 in a physiological setting. CD28 favors binding to monomeric 
counter receptors such as CD86 and monomeric CD80. Intracellular domain 
deletion does not negatively impact CD28 binding but impacts the overall 
cosignaling function due to the lack of association to the cytoskeleton and IS 
localization of these molecules. IgC deletion leads to dimeric and multimeric 
CD80 and CD86 negatively regulating CD28-dependent cosignaling. B) 
Interactions with CTLA-4. For discussion purposes, both CD80 and CD86 are 
presented but CTLA-4:CD80 interactions are more likely than CTLA-4:CD86 in a 
physiological setting. CTLA-4 is a bivalent homodimer that can bind to two 
counter receptors. Although CD86 deleted of its IgC domain is present as a dimer, 
binding is negatively impacted perhaps because CD86 fOTInS asymmetric dimers. 
CD80 deleted of its IgC domain fOTInS high order multimers that are not ideally 
suited for CTLA-4 binding. Intracellular domain deletion in both CD80 and CD86 
does not impact CTLA-4 binding. The physiological impact of such interactions 
remains to be elucidated. 
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4.2 CD80 and CD86 are functionally linked to the APC cytoskeleton 
Interaction between a T cell and an APC during the initiation of adaptive immune 
responses leads to the fonnation of an immunological synapse. At the time where 
the work presented in this thesis was initiated, the importance of the APC and the 
role of APC surface molecules in the context of the IS were ill-defined. The 
prevailing view was that the APC cytoskeleton played a passive role in fonnation 
of such a structure and that APC membrane receptor accumulation at the IS was 
the result of passive diffusion or trapping of these molecules following T cell 
interaction (147, 301-303). The bias of these original studies perhaps stemmed 
from the fact that experiments made use of B cells or artificial lipid bilayers as 
APC and not DC, the only APC capable of activating naïve T cells. Therefore, the 
significance of such a conclusion remained to be established. 
4.2.1 The APC cytoskeleton 
In a 2001 report, AI-Alwan et al.(35) provided evidence for the active role played 
by the DC cytoskeleton in the establishment of the IS. They demonstrated that 
during T cell interaction, the DC actin cytoskeleton is polarized and that DC 
treatment with actin polymerization inhibitors leads to reduced T cell activation. 
They extended their findings in 2003 by showing that DC rearrange their actin 
cytoskeleton only when encountering CD4 T cells presenting a peptide of the 
appropriate specificity and showed that MHC class II signaling plays a central 
role in this process (34). These results highlighted a difference between the APC 
and the T cell cytoskeleton since T cells polarize their cytoskeletal proteins even 
in the absence of specifie antigen recognition. The DC cytoskeleton has also been 
shown to be important in polarizing MHC class II endosomes towards the site of 
T cell contact (32). We showed that the integrity of the cytoskeleton was also 
crucial for effective T cell activation in our interaction model since treatment of 
APC and/or T cells with the cytoskeleton inhibitor latrunculin Bled to an almost 
completely abrogated IL-2 response as shown in figure Il of chapter 3. 
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4.2.2 CD80 and CD86 intracellular do mains interact with the 
cytoskeleton 
In earlier studies, Doty and Clark (225, 226) suggested that CD80 was associated 
to the cytoskeleton since a tailless mutant of CD80 failed to induce T cell 
activation. Two key regions in CD80 intracellular domain (RRNE 275-278 and 
S284) important for CD80 cosignaling function were identified. We confirmed 
CD80 association to the cytoskeleton in Daudi B cells using a biochemical sub-
cellular fractionation technique (figure 6 of chapter 3). Furthermore, CD80 
cytoskeletal association was loss upon deletion of its intracellular domain as 
shown in figure 1 of chapter 2. The functional relevance of such an association 
was also demonstrated in our peptide-specific system by showing that tailless 
CD80 failed to induce significant IL-2 secretion from T cells (figure 5, chapter 2). 
Significantly, subcellular fractionation also revealed that CD86 is associated to 
the cytoskeleton in human DC, B2D cells and 293T cells as shown in figure 1, 
chapter 2 and figure l, chapter 3. We also identified the highly conserved K4 
(275KKKK278) region in CD86 intracellular domain as being crucial for this 
physical linkage. Upon mutation of the four lysines residues to alanines, CD86 
lost its cytoskeletal association, as did a tailless CD86 (figure 1, chapter 3). 
4.2.3 CD80 and CD86 are localized at the IS 
In 2001, Bromley et al. (294) established that CD80 is present at the center of the 
IS. In 2002 Wetzel et al. (153) demonstrated that blockade of CD80:CD28 
interaction alters synapse morphology and leads to reduced T cell proliferation 
(153). Pentcheva-Hoang et al. further defined the importance of CD80 and CD86 
IS localization in a 2004 report (155) by describing a differential activity of CD80 
and CD86 in receptor recruitment at the T cell surface. In agreement with Collins 
et al. (184), CD86, the preferential ligand of CD28, was shown to specifically 
stabilize CD28 at the synapse, while CD80 preferentially recruits and stabilizes 
CTLA-4 at the synapse (155). Finally, in a recent report, Tseng et al. showed that 
the recruitment of CD28 and CTLA-4 by CD80 specifically required its 
cytoplasmic domain (156). 
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As shown in figure 3 of chapter 3, CD86 is present at the IS in both primary 
human DC and in our model APc. These findings were further refined by 
showing that CD86 IS localization is dependent on its cytoskeletal association 
since CD86 mutated in the K4 region failed to redistribute at the interaction 
interface and has a drastically reduced cosignaling function as measured by T cell 
IL-2 secretion. CD86 was also shown to be important for conjugate formation, as 
shown in figure 2 of chapter 3. 
4.2.4 CD86 physically associates with ERM proteins 
The first description of a binding partner for CD86 is demonstrated by co-
immunoprecipitation experiments in the Daudi B cellline where CD86 physically 
associates with ERM proteins (figure 5, chapter 3). ERM proteins act as adapters 
between transmembrane receptors and the cortical actin cytoskeleton. Ezrin has 
been shown to accumulate at the IS (304). Moreover, Tomas et al. showed that 
ezrin localization at the IS is triggered by both TCR and CD28 signaling (117). In 
that same report, ERM pro teins were also shown to be associated to lipid rafts. 
ERM proteins may play a role in the formation or stabilization of signalosomes at 
the IS. Interestingly, a 2004 report by Faure et al. (121) showed that ERM 
proteins function at the IS is tightly regulated by selective phosphorylation. 
Transient Thr dephosphorylation of ERM pro teins in T cells at initial stages of the 
IS leads to cytoskeletal relaxation and more efficient APC:T cell conjugate 
formation. ERM proteins are then rapidly rephosphorylated to act as adapters 
between transmembrane receptors and the cortical actin cytoskeleton. 
4.2.5 The two signal model in APC 
From our results and those of others, a question that remains is the mechanism of 
CD80 and CD86 recruitment at the IS. We propose a reciprocal two-signal model 
in APC that takes into account all previous research. This model is presented in 
figure 3. We have shown that wild type CD86 proteins physically associate with 
ERM proteins. Because CD86 mutated in the K4 region looses its cytoskeletal 
association, we hypothesize that this region is an ERM binding region. 
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1nterestingly, CD80 RRNE region characterized by Doty and Clark (226) also fits 
the definition of an ERM binding region since it is a juxtamembrane positively 
charged cluster. 
The initial signal leading to B7 recruitment at the 1S would occur just following 
the formation of peptide-specific conjugates. This signal could be brought about 
either through direct CD80/CD86 signaling or signaling through other receptors 
such as MHC class II molecules. This first signal would involve the 
phosphorylation of inactive cytoplasmic ERM proteins to adopt open 
conformations. AI-Alwan et al. findings support this first step since it is only in 
the context of specific peptide: MHC clustering that DC rearrange their 
cytoskeleton. The second signal would involve recruitment and/or retention of 
CD86 to the 1S by phosphorylated ERM proteins allowing sustained T cell co-
stimulation. CD80 and CTLA-4 upregulation and interaction would stop 
cosignaling activity. This reciprocal two signal model highlights the bi-directional 
nature of signaling in the 1S that has been described in recent years. 
A B c 
• TCR 
___ Active ERM ~ Cytoskeleton , CTLA-4 
• , , .. MHC:peptide .. Inactive ERM CD28 CD80/CD86 
Figure 3 The Two Signal Model in APC 
A) Signal 1. MHC: peptide cross-link or B7 cross-link (not shown) induces 
signaling events leading to the phosphorylation of ERM proteins. B) Signal 2. 
ERM-bound CD86 localize at the immunological synapse. C) Termination of the 
response by the CD80:CTLA-4 interaction. 
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4.3 Future research 
The work presented in this thesis deepened our understanding of CD80 and CD86 
function; it also opened new research avenues. 
4.3.1 Molecular structure of CD80 and CD86 
The role of CD80 and CD86 IgC in regulating dimerization has been revealed 
from the work presented in this thesis. The exact mechanism by which the IgC 
domain exerts this function remains to be established. Two main hypotheses, not 
mutually exclusive, have been suggested to account for this function of the IgC 
domain. The tirst hypothesis involves the sugar residues within the IgC domain. 
These sugar residues might impact CD80 and CD86 dimerization capacity by 
interacting with the plasma membrane or by creating a shield around these 
molecules. The second hypothesis involves a possible stabilizing interaction 
between the IgC and the IgV domain that could directly impact the dimer 
interface present within the IgV domain. Mutational studies targeting CD80 and 
CD86 glycosylation sites along with the residues believe to be at the interface 
between the IgC and IgV domains could be instigated. FCET, biochemical and 
physiological readouts of the functions of these mutated molecules could deepen 
our understanding of the IgC domain mechanism of action. IgC deleted CD80 and 
CD86 molecules do not bind CD28 as well as their wild type counterparts. This 
can be explained by their existence as higher order multimers. However, the 
observed defect in IL-2 secretion upon T cell activation could also be due to the 
decreased size of the IgC deleted molecules. It would therefore be interesting to 
study the impact of CD80 and CD86 molecular structure in the context of the 
immunological synapse. 
The data presented in this thesis along with the data of others have clearly 
established that CD80 exists as a mixed monomeric and dimeric population. 
Bhatia et al. (257) have suggested that CD80 predominantly exists as a dimer but 
the non-denaturing PAGE experiments performed in the course of this thesis do 
not support such a tinding. Of note, both studies were performed in non-Iymphoid 
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cells. It would be judicious to c1early establish the monomer:dimer ratio of CD80 
molecules at the surface of cells of lymphoid origin, preferably in CD80/CD86 
deficient APc. Moreover, it shaH prove interesting to study the mechanisms by 
which CD80 is expressed as a monomer or as a dimer at the cell surface. 
Although overexpression of CD80 molecules does not change the FRET 
efficiencies, it may affect the proportions between CD80 monomers and dimers. 
This experimental question could be answered by non-denaturing PAGE 
experiments. 
4.3.2. CD80 and CD86 binding partners and signaling 
CD86 and ERM proteins have been shown to physically associate in the Daudi B 
cell line during the course of this thesis. Moreover, data has been gathered in 
recent years on the signaling cascades induced within APC following CD80 and 
CD86 ligation (94, 230, 231, 233, 235). It will be interesting to better delineate 
the region responsible for ERM binding in CD86 and to determine whether CD80 
is also associated to ERM proteins. It shall also prove interesting to establish 
whether ERM proteins can act as signal conveyers through their interaction with 
CD80 and CD86 molecules. A careful analysis of CD80 and CD86 induced 
signaling will certainly lead to a better understanding of the function of these 
molecules. ERM proteins function is regulated by selective phosphorylation in T 
cells. Analysis of the Tyr and Thr phosphorylation of ERM proteins in APC, 
prior, during and following T cell interaction in the context of the IS could lead to 
a better understanding of cytoskeletal dynamics in APc. 
4.3.3. Physiological function of CTLA-4 interactions 
During the course of this thesis, a CD28-dependent cosignaling model was used to 
study the function of CD80 and CD86. To deepen our comprehension of CD80 
and CD86 function, the relevance of CD80 and CD86 cytoskeletal association and 
molecular structure should be assessed in the context of CTLA-4 co-inhibitory 
signaling. 
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In past years, cutting edge microscopy techniques have been developed. To better 
understand the overall function and interplay between CD28/CTLA-
4/CD86/CD80 molecules, the development of models that could allow the study 
of these interactions in real-time peptide-specific live cell interactions or even by 
visualizing these interactions in vivo is of utmost interest. 
4.4 CD80 and CD86 are different 
CD28 and CTLA-4 were discovered 20 years ago and CD80 and CD86 have been 
described over a decade ago. Although considerable progress has been made in 
studying B7 -mediated cosignaling, important functions of these key molecules are 
still being described. Analysis of the properties of the classical members of the 
now extending cosignaling family could certainly help in the study of the newly 
identified molecules. In upcoming years, it will be important to investigate these 
newly described molecules to better understand how their various structures, 
expression levels, binding stochiometry, interaction affinities and signal 
integration regulate their function. AIso, it remains a daunting task to integrate 
data of the multiple signaling pathways from both the IgSF and TNF/TNFR 
cosignaling superfamilies leading to proper T cell activation and function. It will 
be important to integrate all generated data to better understand T cell 
deregulation in auto immune and allergic diseases, to better modulate transplant 
and tumor immunity and for to design new immunotherapeutics. 
In the literature, CD80 and CD86 have been interchangeably used as the CD28 
and CTLA-4 counter receptors. However, our data, combined with that of others, 
clearly show that these molecules are not equivalent. CD86 is a monomeric co-
receptor that is constitutively or rapidly induced at the APC surface and will bind 
to monovalent CD28 inducing a co-activating signal. CD80 is a receptor that can 
be monomeric or dimeric, that is upregulated following initial T cell activation 
and that will bind to bivalent CTLA-4. The structural change that lead to a switch 
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between CD28 monovalent and CTLA-4 bivalent binding could certainly have 
initiated the functional diversification ofthis signaling system (184). 
The work presented in chapter 2 and chapter 3 leads us to a betler understanding 
of the structure and function of these molecules and their constituent domains as 
summarized in figure 4. 
Intracellular 
CD28 and CTLA-4 binding site 
Dimer interface 
Dimerization capacity 
Association to the cytoskeleton 
Figure 4 Role of CD80 and CD86 Functional Domains 
The work accomplished during this thesis as enabled the characterization of CD80 
and CD86 domains function. The IgV domain contains the receptor binding site 
and dimer interface. The IgC domains negatively regulate dimer formation for 
both molecules. Moreover, the intracellular domains of both molecules are 
functionally linked to the cytoskeleton. Altogether, all 3 domains of CD80 and 
CD86 are important for their full cosignaling function. 
The results highlight the distinct yet coupled roI es of CD80 and CD86 domains. 
The binding region resides in the IgV portions of CD80 and CD86 along with the 
dimer interface. This dimer interface is stabilized through the IgC domain 
interaction with the plasma membrane and/or with the IgV domain directly 
impacting the receptor binding properties and overall function. Finally, CD80 and 
CD86 intracellular domains functionally link these molecules to the cytoskeleton. 
Altogether, the results acquired during the course of this thesis have established 
the functional role of CD80 and CD86 domains in their molecular structure and 
overall cosignaling function. These results may facilitate the design of structure-
based immunotherapeutics. 
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Antibody Stainings Gating Strategy and Exemplary Histograms 
1. Gating on live cells (P1) 
2. Gating on equal MFI populations (P2 or P3) 
3. PE signal histogram on selected populations (P2) 
C080wt Ab L307 4 PE 
50ecimen OO'-CDBD L3074 PE 
i--
O!I-
1'1-
§~ P5 
810-
~ 
~ 
.,.; 
ID' 10' ID· ,,' 
PE-A 
w' 1~ w· w5 
CFP-A 
C080 C· Il Isotvoe PE 
SDeclmen OO'-CD80dC 
'"' i--
~ 
1'1-
~~ P5 
u~ 
~ 
~ 
"" 
ID' ID' ID· ,,' 
PE-A 
10:1 106 
PE-A 
C080llC Ab L307.4 PE 
P5 
,.' 
Appendix 5 
178 
! 
<1-
"" 6
'" 
Cf) 
Ligand Binding by FACS: Gating Strategy and Exemplary Histograms 
Gating Strategy 
1. Live cells gating (P1) 
2. Equal MFI Gating (P2, P3 and P4) 
3. Alexa 647 Signal Histogram on Selected Populations (P5/P6/P7 
parent of P2/P3/P4) 
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